Apatinib Clinical Trials (2026): 787 Studies for Breast Cancer & Neoplasms, Breast
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
787 Apatinib clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 330 indications (including Breast Cancer & Neoplasms, Breast) and 96,153 total planned enrollment. 84 Phase 3 Apatinib trials and 476 Phase 2, 10 Phase 4 are listed. 110 Apatinib clinical trials are actively recruiting. Most recent activity: NCT04581473 (Jun 2038).
Apatinib clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 3 | 2 | 1 | 6 | |||||||
| P1 | 2 | 1 | 60 | 13 | 2 | 16 | 94 | ||||
| P1/P2 | 4 | 1 | 13 | 6 | 1 | 23 | 48 | ||||
| P2 | 45 | 10 | 1 | 131 | 42 | 14 | 1 | 27 | 205 | 476 | |
| P2/P3 | 2 | 2 | 2 | 1 | 13 | 20 | |||||
| P3 | 14 | 6 | 29 | 4 | 3 | 28 | 84 | ||||
| P4 | 4 | 1 | 5 | 10 | |||||||
| N/A | 7 | 13 | 3 | 2 | 1 | 3 | 19 | 1 | 49 |
Recruiting Apatinib clinical trials (110)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT04803539 | ArtemisA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | P2/P3 | Breast Cancer | 260 | Apr 2021 |
| NCT07267806 | Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC | P3 | Hepato Cellular Carcinoma (HCC) | 326 | Oct 2025 |
| NCT06831175 | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma | P2 | Adrenal Cortical Carcinoma | 28 | Mar 2025 |
| NCT06576973 | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | P2 | Esophageal Squamous Cell Carcinoma | 35 | Aug 2024 |
| NCT06255392 | Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | P3 | Fludzoparib" and Anti-angiogenic | 200 | Jun 2024 |
| NCT06925243 | Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | P3 | Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]) | 682 | Apr 2025 |
| NCT06773156 | Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | P2 | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 37 | Nov 2024 |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | P2 | Gastric Adenocarcinoma | 80 | Apr 2026 |
| NCT07309419 | Cocktail-001A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | P2/P3 | Hepatocellular Carcinoma | 222 | Dec 2025 |
| NCT07026149 | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer | P2 | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | 30 | Jun 2025 |
| NCT06881017 | Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping | P2 | Gastric Cancer | 140 | May 2025 |
| NCT05582499 | FASCINATE-NFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | P2 | Breast Neoplasm | 716 | Nov 2022 |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | P3 | BCLC Stage C Hepatocellular Carcinoma | 262 | Jul 2023 |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | P3 | Breast Cancer Stage IV | 246 | Feb 2025 |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | P3 | Nasopharyngeal Carcinoma | 164 | May 2024 |
| NCT06771154 | A-CAPEAdebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial | P2 | Recurrent/Metastatic Endometrial Cancer | 140 | Apr 2025 |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | P2 | Intrahepatic Cholangiocarcinoma | 20 | Mar 2024 |
| NCT06181032 | A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies | P1 | Biliary Tract Malignancies | 35 | Dec 2023 |
| NCT06447623 | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer | P3 | Advanced Breast Cancer | 184 | Feb 2024 |
| NCT07324473 | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study | P2 | Hepatocellular Carcinomas | 65 | Jan 2026 |
| NCT07314372 | FAD-HCC-001FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma | P2 | Unresectable Hepatocellular Carcinoma (HCC) | 86 | Feb 2026 |
| NCT07371871 | TAS-102A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer | N/A | Advanced Gastric Cancer | 30 | Jan 2026 |
| NCT07569679 | Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer | P2 | Biliary Tract Cancer | 124 | Dec 2025 |
| NCT07135544 | A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer | P2 | Biliary Tract Cancer | 37 | Aug 2025 |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | P2 | Small Cell Lung Carcinoma | 44 | Jan 2026 |
| NCT06925516 | ACADEMYA Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC | P2 | Intrahepatic Cholangiocarcinoma (Icc) | 38 | Apr 2025 |
| NCT06786312 | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | P2 | Small Cell Lung Cancer Extensive Stage | 34 | Jan 2025 |
| NCT06339619 | Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | P2 | Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma | 32 | Mar 2024 |
| NCT07314203 | SOP-XH-IRBClinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer | P3 | Gastric Cancer | 118 | Dec 2026 |
| NCT07105748 | TASK-05HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) | P2 | Mixed Hepatocellular-cholangiocarcinoma | 45 | Aug 2025 |
| NCT07294664 | PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer | P2 | Advanced Gastric Cancer | 78 | Jun 2025 |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | P2 | Salivary Gland Carcinoma | 39 | Aug 2023 |
| NCT05934331 | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study | P2 | Malignant Neoplasms of Digestive Organs | 276 | Jul 2023 |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | P3 | Unresectable Hepatocellular Carcinoma | 101 | Aug 2024 |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | P2 | Oral Squamous Cell Carcinoma | 46 | Sep 2021 |
| NCT06759090 | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | P2 | Metastatic Pancreatic Carcinoma | 43 | Jan 2025 |
| NCT07033819 | Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib | P2 | Ovarian Cancer | 48 | Jun 2025 |
| NCT06764368 | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors | P2 | Neuroendocrine Tumors | 39 | Jan 2025 |
| NCT07236528 | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | P2 | Mucosal Melanoma | 30 | Nov 2025 |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | P2 | Adebrelimab | 49 | May 2025 |
| NCT06385873 | RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer | P2 | Gastric Cancer/Gastroesophageal Junction Adenocarcinoma | 32 | May 2024 |
| NCT06280508 | Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer | P2 | Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence | 40 | Mar 2024 |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | P2 | Unresectable Hepatocellular Carcinoma | 111 | Jan 2024 |
| NCT06893887 | ICT-HCCIndividualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma | N/A | Hepatocellular Carcinoma(HCC) | 300 | May 2025 |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | P2 | Advanced Esophageal Carcinoma | 63 | Feb 2025 |
| NCT06607107 | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria | P2 | Hepatocellular Carcinoma Non-resectable | 29 | Feb 2024 |
| NCT07479732 | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | P1/P2 | Osteosarcoma | 56 | Mar 2026 |
| NCT06538935 | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma | P2 | Hepatocellular Carcinoma | 80 | Jan 2025 |
| NCT06749691 | LIAESLiposomal Irinotecan and Apatinib in ES-SCLC | P2 | Small Cell Lung Cancer Extensive Stage | 30 | Dec 2024 |
| NCT07334483 | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC | P2 | HCC | 120 | Aug 2025 |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | P3 | Nasopharyngeal Carcinoma | 244 | May 2023 |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | P3 | Hepatocellular Carcinoma | 130 | Jan 2023 |
| NCT02029001 | MOST plusAdapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment | P2 | Malignant Solid Neoplasms | 900 | Mar 2014 |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | P2 | Locally Advanced Gastric Cancer | 203 | Sep 2022 |
| NCT04072042 | BIOVASBIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma | P2 | Sarcoma | 30 | Oct 2019 |
| NCT06607770 | Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers | P1/P2 | Lung Cancer | 20 | Sep 2024 |
| NCT06537505 | A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors | P2 | Solid Tumor | 60 | Aug 2024 |
| NCT07192848 | Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy | P2 | Hepatocellular Carcinoma Non-resectable | 47 | Sep 2025 |
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | P2 | HCC - Hepatocellular Carcinoma | 300 | Feb 2025 |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | P2 | Carcinoma, Hepatocellular | 30 | Jul 2024 |
| NCT06749730 | GPAdebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma | P2 | Unresectable Biliary Tract Carcinoma | 63 | Apr 2024 |
| NCT05759572 | Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer | P2 | Breast Cancer Metastatic | 145 | Feb 2023 |
| NCT06415669 | A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma | P2 | Gastric/Gastroesophageal Junction Adenocarcinoma | 30 | May 2024 |
| NCT06973330 | Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma | P2 | AFP Gastric or Gastroesophageal Junction Adenocarcinoma | 40 | Jul 2025 |
| NCT06792162 | PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer | P2 | Gastric Cancer | 20 | Apr 2023 |
| NCT06913777 | Neoadjuvant SNF Precision Therapy Phase III | P3 | Neoadjuvant Therapy | 404 | Apr 2025 |
| NCT05699655 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | P2/P3 | Immunotherapy Gastrict Cancer | 130 | May 2023 |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | P2 | Esophageal Cancer by AJCC V8 Stage | 188 | Mar 2023 |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | P3 | Acral Melanoma | 140 | Mar 2023 |
| NCT07031154 | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | P2 | Non-Small Cell Lung Cancer | 43 | Jun 2025 |
| NCT05751733 | Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | N/A | Gastrointestinal Stromal Tumors | 258 | Feb 2023 |
| NCT05139095 | Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia | P2 | Gestational Trophoblastic Neoplasia | 70 | Jan 2022 |
| NCT06418594 | Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis | P2 | HER2-negative Breast Cancer Brain Metastases | 30 | Oct 2024 |
| NCT06483282 | A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer | P2 | Small Cell Lung Cancer Limited Stage | 38 | Jun 2024 |
| NCT06339281 | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | P2 | Advanced Breast Cancer | 68 | May 2024 |
| NCT06099821 | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | P2 | Digestive System Cancers | 39 | Oct 2023 |
| NCT05447702 | TNBCStudy of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | P2 | Triple Negative Breast Cancer | 35 | Nov 2022 |
| NCT04331093 | Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma | P2 | Acral Melanoma | 40 | Mar 2021 |
| NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | P2 | Liver Cancer | 46 | Oct 2024 |
| NCT06081595 | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | P2 | Relapsed Ovarian Cancer | 54 | Oct 2023 |
| NCT06475209 | Adebrelimab + Apatinib in SCLC Maintenance Therapy | P2 | SCLC | 60 | Jun 2024 |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | P3 | Ovarian Cancer | 37 | Dec 2024 |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | P2 | Dedifferentiated Liposarcoma | 49 | Dec 2024 |
| NCT05594095 | SNF Platform Study of HR+/ HER2-advanced Breast Cancer | P2 | Breast Neoplasm | 620 | Dec 2022 |
| NCT06339216 | A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | P2 | Gastric Cancer | 30 | Mar 2024 |
| NCT06102707 | The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients | N/A | Ovarian Cancer Recurrent | 50 | Nov 2023 |
| NCT06485271 | A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer | — | Gastric Cancer | 504 | Nov 2023 |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | P3 | Epithelial Ovarian Cancer | 51 | Oct 2024 |
| NCT06592287 | The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer | P1/P2 | Advanced Gastric Cancer | 66 | Sep 2024 |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | P2 | Hepatocellular Carcinoma | 38 | Aug 2024 |
| NCT05479487 | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | P2 | Relapsed Ovarian Cancer | 132 | Aug 2022 |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | P3 | Gastric Cancer | 550 | Sep 2020 |
| NCT06769425 | HS-10502HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | P1 | Recurrent Ovarian Cancer | 157 | May 2025 |
| NCT06480864 | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | N/A | Small Cell Lung Cancer | 38 | Aug 2024 |
| NCT06464614 | Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. | P2 | Esophageal Cancer | 54 | Jul 2024 |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | P2 | Stage III Hepatocellular Cancer (CNLC Staging) | 35 | Jun 2022 |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | P2 | Hepatocellular Carcinoma | 33 | Apr 2024 |
| NCT06313983 | A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | P3 | Breast Cancer | 339 | Jan 2022 |
| NCT04831528 | Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study | — | Metastatic Colorectal Cancer | 100 | Apr 2021 |
| NCT06429696 | PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer | P2 | Small Cell Lung Cancer Extensive Stage | 40 | Jul 2024 |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. | P1/P2 | Neuroblastoma | 125 | Aug 2021 |
| NCT06482008 | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | P2 | Hepatocellular Carcinoma | 33 | Jun 2024 |
| NCT05713994 | CCGLC-001Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | Hepatocellular Carcinoma Non-resectable | 300 | May 2020 |
| NCT03736863 | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | P2 | Esophageal Cancer | 147 | Dec 2019 |
| NCT05192798 | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | P2 | Triple-negative Breast Cancer | 128 | Jan 2022 |
| NCT06482086 | Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer | P2 | Locally Advanced Thyroid Gland Carcinoma | 75 | Jun 2021 |
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | P2 | Recurrent Medulloblastoma | 44 | Oct 2020 |
| NCT04501705 | Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults | N/A | Recurrent Atypical/malignant Meningioma | 29 | Aug 2020 |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | P1/P2 | Advanced Triple Negative Breast Cancer | 29 | Oct 2021 |
| NCT05717738 | CCGLC-008Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Hepatocellular Carcinoma Non-resectable | 300 | Jan 2022 |
Apatinib clinical trials by indication
Breast Cancer (67)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04803539 | Artemis | P2/P3 | recruiting | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC |
| NCT03982485 | APP | P2 | active not recruiting | Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer |
| NCT06313983 | — | P3 | recruiting | A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer |
| NCT00999804 | HELEX | P2 | active not recruiting | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy |
| NCT03523585 | — | P3 | completed | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] |
| NCT01104571 | EPHOS-B | P3 | unknown | Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer |
| NCT04591431 | ROME | P2 | unknown | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy |
| NCT00470704 | — | P2 | completed | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer |
| + 59 more, see All trials below. | ||||
Neoplasms, Breast (43)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00251433 | — | P1 | terminated | GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer |
| NCT01160211 | — | P3 | completed | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer |
| NCT00281658 | — | P3 | completed | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 |
| NCT00490139 | ALTTO | P3 | completed | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D |
| NCT00508274 | — | P3 | terminated | Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China |
| NCT00444535 | — | P2 | completed | Lapatinib and Bevacizumab for Metastatic Breast Cancer |
| NCT02213042 | — | P2 | terminated | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer |
| NCT03273595 | — | P2 | unknown | Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer |
| + 35 more, see All trials below. | ||||
Gastric Cancer (40)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06881017 | — | P2 | not yet recruiting | Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping |
| NCT07314203 | SOP-XH-IRB | P3 | not yet recruiting | Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer |
| NCT06792162 | — | P2 | recruiting | PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer |
| NCT06339216 | — | P2 | not yet recruiting | A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. |
| NCT06485271 | — | N/A | recruiting | A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer |
| NCT06346392 | — | P3 | active not recruiting | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 |
| NCT04342910 | — | P3 | recruiting | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC |
| NCT05853172 | AK104 | P2 | unknown | Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer |
| + 32 more, see All trials below. | ||||
Hepatocellular Carcinoma (34)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07309419 | Cocktail-001 | P2/P3 | not yet recruiting | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma |
| NCT06538935 | — | P2 | not yet recruiting | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma |
| NCT05613478 | — | P3 | recruiting | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma |
| NCT06546280 | — | P2 | not yet recruiting | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation |
| NCT05320692 | — | P3 | active not recruiting | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma |
| NCT05198609 | — | P3 | active not recruiting | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial |
| NCT06349317 | — | P2 | recruiting | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT |
| NCT04521153 | — | P2/P3 | active not recruiting | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
| + 26 more, see All trials below. | ||||
Metastatic Breast Cancer (28)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07371910 | — | P3 | active not recruiting | Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer |
| NCT01526369 | TH V THL | P3 | completed | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer |
| NCT02650752 | CNS | P1 | completed | Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases |
| NCT02073916 | STELA | P1 | completed | T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer |
| NCT01300962 | — | P1 | completed | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer |
| NCT00759642 | — | P2 | terminated | Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy |
| NCT01730677 | LV | P2 | unknown | Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab |
| NCT02238509 | — | P2 | unknown | Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies |
| + 20 more, see All trials below. | ||||
Ovarian Cancer (18)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07033819 | — | P2 | recruiting | Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib |
| NCT06188455 | — | P3 | not yet recruiting | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer |
| NCT06161272 | — | P2 | unknown | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi |
| NCT05597527 | — | P2 | unknown | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer |
| NCT04608409 | — | P1 | completed | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer |
| NCT04229615 | — | P3 | unknown | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy |
| NCT04590625 | — | P2 | unknown | Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer |
| NCT04000295 | — | P3 | unknown | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer |
| + 10 more, see All trials below. | ||||
Cancer (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03396211 | — | P1 | completed | A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer |
| NCT01636908 | ICK | N/A | completed | Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. |
| NCT00968968 | — | P3 | terminated | Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone |
| NCT02294786 | — | P2 | terminated | Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer |
| NCT01332396 | — | N/A | completed | Drug Use Investigation for TYKERB Tablet (All Case Investigation) |
| NCT01013740 | VITAL | P2 | completed | Lapatinib in Combination With Vinorelbine |
| NCT01328054 | — | P4 | completed | A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval |
| NCT01077648 | — | N/A | completed | Brain Metastasis in Breast Cancer Patients |
| + 4 more, see All trials below. | ||||
Nasopharyngeal Carcinoma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06438627 | — | P3 | recruiting | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial |
| NCT05854849 | — | P3 | recruiting | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC |
| NCT05549466 | — | P2 | unknown | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC |
| NCT04548271 | — | P2 | unknown | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma |
| NCT04547088 | — | P2 | unknown | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma |
| NCT04586088 | — | P2 | unknown | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure |
| NCT04350190 | — | P2 | completed | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma |
| NCT03612219 | — | P2 | unknown | Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma |
| + 2 more, see All trials below. | ||||
Breast Neoplasms (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01273610 | — | P2 | active not recruiting | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer |
| NCT07416409 | — | N/A | completed | Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer |
| NCT03500380 | — | P2/P3 | unknown | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases |
| NCT00073528 | GW572016 | P3 | completed | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer |
| NCT01499160 | — | P2 | terminated | Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer |
| NCT01875666 | — | Early P1 | completed | Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib |
| NCT01557764 | — | P2 | withdrawn | Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer |
| NCT01272141 | — | P2 | terminated | A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer |
| + 2 more, see All trials below. | ||||
Colorectal Cancer (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03193814 | XHZL | P2 | withdrawn | Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer |
| NCT04446091 | MAC | P1/P2 | unknown | A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) |
| NCT03397199 | — | P2 | unknown | Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer |
| NCT03377842 | — | P2 | unknown | Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer |
| NCT03403452 | — | P2 | unknown | Apatinib in the Treatment of Metastatic Colorectal Cancer |
| NCT02230553 | M14LTK | P1/P2 | completed | Lapatinib Plus Trametinib in KRAS Mutant NSCLC |
| NCT03344614 | — | P2 | unknown | A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer |
| NCT01531777 | — | P2 | completed | Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer |
| + 2 more, see All trials below. | ||||
Esophageal Squamous Cell Carcinoma (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06576973 | — | P2 | recruiting | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma |
| NCT06281886 | — | P2 | active not recruiting | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma |
| NCT03857763 | — | P2 | unknown | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma |
| NCT02976896 | Poetry-1 | P2 | completed | Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment |
| NCT03913182 | — | P2 | unknown | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer |
| NCT03251417 | — | P2 | terminated | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma |
| NCT03603756 | — | P2 | unknown | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer |
| NCT03224221 | — | P2 | unknown | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment |
| + 1 more, see All trials below. | ||||
Advanced Gastric Cancer (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07371871 | TAS-102 | N/A | not yet recruiting | A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer |
| NCT07294664 | — | P2 | recruiting | PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer |
| NCT06592287 | — | P1/P2 | not yet recruiting | The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer |
| NCT04195828 | — | P2 | completed | Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer |
| NCT04182724 | — | P1/P2 | unknown | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer |
| NCT04286711 | — | P1/P2 | unknown | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer |
| NCT03954756 | — | P2 | unknown | Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer |
| NCT03255811 | — | N/A | unknown | Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer |
Small Cell Lung Cancer (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06480864 | — | N/A | recruiting | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer |
| NCT02875457 | — | P3 | unknown | Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin |
| NCT04128800 | — | P2 | unknown | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer |
| NCT03389087 | — | P2 | unknown | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer |
| NCT03651219 | — | P3 | unknown | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer |
| NCT02980809 | — | P2 | unknown | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer |
| NCT02945852 | — | P2 | completed | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. |
| NCT02995187 | SCLC | P2 | unknown | Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) |
Gastric Adenocarcinoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04581473 | — | P1/P2 | active not recruiting | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
| NCT07464756 | — | P2 | not yet recruiting | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer |
| NCT04190745 | — | P2 | unknown | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study |
| NCT04121039 | — | P2 | unknown | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer |
| NCT03788174 | — | P2 | unknown | Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma |
| NCT03707639 | — | P2 | unknown | Study of the Combination of Apatinib and POF |
| NCT03244774 | — | P1 | unknown | Phase I Study of the Combination of Apatinib and POF |
Lung Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06607770 | — | P1/P2 | recruiting | Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers |
| NCT03164694 | APPEAL | P2 | withdrawn | APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC |
| NCT04782622 | — | N/A | unknown | The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy |
| NCT04201990 | CCA-MPLC | P1/P2 | unknown | Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer |
| NCT03411967 | — | P2 | unknown | Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC |
| NCT03201146 | — | P1/P2 | unknown | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC |
| NCT02704767 | — | P2 | unknown | Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma |
Intrahepatic Cholangiocarcinoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06296563 | — | P2 | recruiting | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC |
| NCT04834674 | — | P2 | completed | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma |
| NCT04454905 | — | P2 | unknown | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study |
| NCT05400902 | — | P2 | unknown | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma |
| NCT05290116 | — | P2 | unknown | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma |
| NCT03521219 | — | P2 | unknown | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma |
| NCT03251443 | — | P2 | completed | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma |
NSCLC (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05932264 | — | P2 | unknown | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer |
| NCT04506242 | — | P2 | unknown | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer |
| NCT03801200 | — | P2 | unknown | Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC |
| NCT04390984 | — | P1 | unknown | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients |
| NCT03428022 | AFLC | P3 | unknown | Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC |
| NCT03634059 | — | N/A | unknown | A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations |
| NCT03416231 | NSCLC | P2 | unknown | Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) |
Non-small Cell Lung Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04950400 | — | N/A | unknown | A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC |
| NCT04968002 | — | P2/P3 | unknown | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy |
| NCT02733107 | — | P2 | unknown | The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer |
| NCT03129256 | EASE | P2 | completed | An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer |
| NCT02780778 | — | P2/P3 | unknown | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer |
| NCT02540824 | — | P2 | unknown | Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer |
| NCT01287962 | — | P3 | unknown | Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer |
Esophageal Cancer (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06464614 | — | P2 | not yet recruiting | Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. |
| NCT03736863 | — | P2 | recruiting | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
| NCT05049681 | — | P3 | unknown | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell |
| NCT03671265 | — | N/A | unknown | Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC |
| NCT02544737 | — | P2 | unknown | Apatinib for Metastatic Esophageal Cancer. |
| NCT02683655 | — | P2 | unknown | Study of Apatinib in Metastatic Esophageal Cancer |
Osteosarcoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07479732 | — | P1/P2 | recruiting | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma |
| NCT06125171 | — | P2 | unknown | Tucidinostat Plus Apatinib for Advanced Osteosarcoma |
| NCT03742193 | PROACH | P2 | unknown | Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy |
| NCT04351308 | MAPAC | P2 | unknown | Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma |
| NCT02711007 | — | P2/P3 | completed | Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy |
Biliary Tract Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07569679 | — | P2 | recruiting | Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer |
| NCT07135544 | — | P2 | recruiting | A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer |
| NCT04720131 | — | P2 | completed | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. |
| NCT04642664 | ACABC | P2 | completed | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer |
| NCT03144856 | — | P2 | unknown | Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers |
Head and Neck Squamous Cell Carcinoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05189184 | HNSCC | P2 | unknown | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma |
| NCT04440917 | IMplus | P2 | unknown | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma |
| NCT03267121 | — | P2 | completed | A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck |
| NCT03424291 | — | P2 | unknown | A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma |
| NCT03096184 | — | P2 | unknown | A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers |
Metastatic Colorectal Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04831528 | — | N/A | not yet recruiting | Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study |
| NCT03225937 | HERACLES | P2 | unknown | Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer |
| NCT03210064 | — | P2 | unknown | Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients |
| NCT03132025 | — | P2 | unknown | Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer |
| NCT00574171 | — | P2 | completed | Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma |
Colorectal Neoplasms (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03743428 | BABST-C | N/A | suspended | Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C) |
| NCT03271255 | ABST-C | P2 | unknown | Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) |
| NCT03412994 | — | P2 | unknown | Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer |
| NCT03190616 | — | P2 | completed | Apatinib in Refractory Colorectal Cancer |
| NCT02829385 | — | P2 | unknown | Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients |
Sarcoma (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04072042 | BIOVAS | P2 | recruiting | BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma |
| NCT04074564 | — | Early P1 | unknown | MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma |
| NCT04447274 | — | P2 | unknown | A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS |
| NCT03711279 | — | P2 | terminated | A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma |
| NCT04126993 | — | P2 | unknown | Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma |
Head and Neck Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01612351 | — | P2 | completed | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery |
| NCT03654612 | Y-HR2017-025 | P1/P2 | unknown | Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies |
| NCT01044433 | — | P2 | completed | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck |
| NCT00490061 | — | P2 | terminated | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy |
| NCT00498953 | — | P1/P2 | completed | Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx |
Advanced Solid Tumors (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02844881 | — | P1/P2 | unknown | Study of Apatinib and MASCT in Patients With Advanced Solid Tumors |
| NCT01190241 | TSAP | N/A | terminated | Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study |
| NCT01497626 | — | P1 | terminated | Lapatinib and Bortezomib in Patients With Advanced Malignancies |
| NCT00963547 | MK-2206-015 | P1 | terminated | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) |
| NCT00682279 | — | P1 | withdrawn | A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors |
Hepatocellular Carcinoma Non-resectable (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06607107 | — | P2 | recruiting | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria |
| NCT07192848 | — | P2 | not yet recruiting | Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy |
| NCT05713994 | CCGLC-001 | N/A | recruiting | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
| NCT05717738 | CCGLC-008 | N/A | recruiting | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma |
Small Cell Lung Cancer Extensive Stage (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06786312 | — | P2 | not yet recruiting | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer |
| NCT06749691 | LIAES | P2 | recruiting | Liposomal Irinotecan and Apatinib in ES-SCLC |
| NCT06429696 | — | P2 | recruiting | PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer |
| NCT04659785 | — | P1/P2 | unknown | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） |
Solid Tumor (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06537505 | — | P2 | not yet recruiting | A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors |
| NCT05380986 | — | N/A | unknown | Camrelizumab Combined With Apatinib Mesylate |
| NCT04832204 | — | P2 | unknown | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases |
| NCT04569916 | — | P2 | unknown | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors |
Metastatic Gastric Adenocarcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04781686 | — | P2 | unknown | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer |
| NCT05342389 | — | P2 | unknown | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer |
| NCT03116555 | — | P2 | unknown | Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA |
| NCT03071042 | — | P1 | unknown | A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma |
Soft Tissue Sarcoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03784014 | MULTISARC | P3 | completed | Molecular Profiling of Advanced Soft-tissue Sarcomas |
| NCT04012827 | — | P2 | unknown | Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma |
| NCT04126811 | — | P2 | unknown | Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma |
| NCT03064243 | — | P2 | unknown | A Phase II Study of Apatinib in STS Patients |
Glioma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03741244 | — | P2 | unknown | TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT |
| NCT03390062 | — | P2 | unknown | A Study of Apatinib in Recurrent or Recurrent High-grade Glioma |
| NCT00107003 | — | P2 | completed | GW572016 to Treat Recurrent Malignant Brain Tumors |
| NCT00350727 | VEG102857 | P2 | completed | Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma |
Gastric Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03355612 | — | P3 | unknown | XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma |
| NCT03599778 | — | P1/P2 | unknown | XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma |
| NCT02409199 | — | P2/P3 | unknown | A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer |
| NCT00970138 | — | P2/P3 | completed | Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer |
HER2-positive Breast Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01873833 | — | P2 | terminated | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer |
| NCT03085368 | — | P2/P3 | unknown | A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin |
| NCT01688609 | — | P2 | completed | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer |
| NCT01245205 | — | P1 | completed | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer |
Small Cell Lung Carcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07357532 | — | P2 | not yet recruiting | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD |
| NCT04453930 | — | P2 | unknown | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） |
| NCT04901754 | CAMERA | P2 | unknown | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer |
Non-Small Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07031154 | — | P2 | not yet recruiting | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer |
| NCT04878107 | SABRE | P2 | unknown | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy |
| NCT02515435 | — | P2 | unknown | The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer |
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07026149 | — | P2 | recruiting | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer |
| NCT06693128 | — | P2 | active not recruiting | Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer |
| NCT04208347 | — | P2/P3 | active not recruiting | Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer |
Carcinoma, Hepatocellular (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06454578 | — | P2 | recruiting | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection |
| NCT03261791 | — | P2 | unknown | Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection |
| NCT02329860 | AHELP | P3 | completed | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) |
Advanced Breast Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06447623 | — | P3 | recruiting | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer |
| NCT06339281 | — | P2 | not yet recruiting | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer |
| NCT00777101 | — | P2 | completed | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer |
Relapsed Ovarian Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06081595 | — | P2 | not yet recruiting | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment |
| NCT05479487 | — | P2 | not yet recruiting | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment |
| NCT04517357 | — | P2 | completed | A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients |
Triple Negative Breast Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05447702 | TNBC | P2 | recruiting | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) |
| NCT03945604 | — | P1 | completed | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC |
| NCT03348098 | — | P2 | unknown | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer |
Effect of Drug (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04824352 | AIEO | P2 | suspended | Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma |
| NCT05277480 | OAIE | P2 | completed | Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) |
| NCT04690231 | — | N/A | completed | Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma |
Triple-negative Breast Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05192798 | — | P2 | recruiting | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC |
| NCT03932526 | — | P2 | unknown | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer |
| NCT03775928 | — | P2 | unknown | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer |
Small-cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04683198 | — | P2 | unknown | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC |
| NCT03417895 | PASSION | P2 | completed | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy |
| NCT03547804 | MK 01 | P2 | completed | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer |
Thyroid Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04612894 | — | P2 | unknown | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer |
| NCT02731352 | — | P2 | completed | Study of Apatinib in Patients With Differentiated Thyroid Cancer |
| NCT03300765 | — | P2 | unknown | Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer |
Advanced Solid Tumor (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04282278 | — | P2 | unknown | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor |
| NCT04457180 | — | P1 | completed | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects |
| NCT04322552 | — | P1 | completed | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects |
Metastatic Pancreatic Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04101929 | — | P2 | unknown | Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen |
| NCT02863367 | OECTAPGAMPC | P2 | unknown | A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer |
| NCT00447122 | — | P1 | terminated | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer |
Advanced Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03645200 | — | P1 | unknown | Treatment of Carrying TP53 Harmful Mutations |
| NCT00543504 | — | P1 | completed | Bevacizumab in Multiple Phase I Combinations |
| NCT03243643 | HS:Hansoh; | P1 | unknown | Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors |
Nonsmall Cell Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03050411 | — | P1 | unknown | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer |
| NCT03256721 | — | P2 | terminated | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC |
| NCT02974933 | — | P2 | unknown | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer |
Carcinoma, Non-Small-Cell Lung (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01306045 | — | P2 | completed | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies |
| NCT03083041 | NSCLC | P2 | completed | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) |
| NCT02332512 | ANSWER | P3 | unknown | Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) |
Unspecified Adult Solid Tumor, Protocol Specific (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00662636 | — | P1 | completed | Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery |
| NCT00389922 | — | P1 | completed | Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors |
| NCT00804310 | UCDCC#207 | P1 | terminated | Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors |
Bladder Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00313599 | — | P1 | completed | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors |
| NCT00623064 | — | P1 | completed | Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer |
| NCT00949455 | LaMB | P2/P3 | unknown | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium |
Neoplasms, Gastrointestinal Tract (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00680901 | HER2 | P3 | completed | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib |
| NCT00526669 | — | P2 | completed | Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib |
| NCT00486954 | — | P3 | completed | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer |
Mucosal Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07236528 | — | P2 | not yet recruiting | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma |
| NCT03986515 | — | P2 | unknown | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma |
HCC (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07334483 | — | P2 | recruiting | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC |
| NCT04165174 | — | P2 | unknown | PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT |
Unresectable Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06485466 | — | P3 | recruiting | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma |
| NCT06360042 | — | P2 | recruiting | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC |
Advanced Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05924997 | — | P1/P2 | unknown | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma |
| NCT01192971 | HCC | P2 | completed | A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma |
Acral Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05789043 | — | P3 | recruiting | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma |
| NCT04331093 | — | P2 | recruiting | Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma |
Breast Cancer Metastatic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05759572 | — | P2 | recruiting | Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer |
| NCT03086785 | — | P2 | unknown | Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer |
Breast Neoplasm (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05582499 | FASCINATE-N | P2 | recruiting | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy |
| NCT05594095 | — | P2 | recruiting | SNF Platform Study of HR+/ HER2-advanced Breast Cancer |
Locally Advanced Gastric Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05524974 | — | P2 | not yet recruiting | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes |
| NCT04792515 | CCWSA/OAFLAG | P2 | unknown | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer |
C-staged Hepatocellular Carcinoma in BCLC Classification (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04191889 | TRIPLET | P2 | unknown | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification |
| NCT05313282 | TRIPLET-III | P3 | unknown | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification |
Advanced Gastric Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06238752 | RENMIN-213 | P2 | completed | First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC |
| NCT04174339 | SHR-1210 | N/A | unknown | PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer |
Non Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03758677 | — | P2 | unknown | Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation |
| NCT03811054 | NSCLC | P2 | unknown | The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) |
Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04415385 | — | P2 | unknown | The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma |
| NCT00962312 | — | P2 | completed | Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer |
Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04397770 | — | P2 | unknown | Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma |
| NCT03955354 | — | P2 | unknown | PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma |
Healthy Subjects (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04341090 | — | P1 | completed | A Food Effect Study of Apatinib Mesylate in Healthy Subjects |
| NCT00513253 | — | P1 | withdrawn | A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib |
Apatinib (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03228043 | — | N/A | withdrawn | Apatinib for Resectable Colorectal Cancer |
| NCT03365765 | — | P3 | completed | mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer |
Recurrent Cervical Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03816553 | — | P2 | completed | SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer |
| NCT04188847 | — | P2 | completed | First-line Chemotherapy for Recurrent Cervical Cancer |
Lung Diseases (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03389256 | — | P2 | unknown | Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC |
| NCT04133337 | — | P1/P2 | unknown | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC |
Efficacy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04260113 | AIAC | N/A | completed | Apatinib for Inoperable Advanced Chondrosarcoma |
| NCT03491371 | — | N/A | completed | Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use |
Gastroesophageal Junction Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03986385 | — | P3 | unknown | Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction |
| NCT03349866 | — | P2 | unknown | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction |
Stomach Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02485015 | — | P2 | active not recruiting | The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer |
| NCT03889626 | — | P3 | unknown | The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer |
Advanced Non-squamous Non-small-cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03792503 | — | P4 | withdrawn | Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen |
| NCT03190239 | XQonc-007 | P2 | withdrawn | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients |
Advanced Non Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04239443 | — | P2 | unknown | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer |
| NCT03652857 | — | P2 | completed | Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer |
Esophageal Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03787251 | — | P2 | withdrawn | A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib |
| NCT03274011 | — | P2 | completed | Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
Advanced Esophagus Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03170310 | — | P2 | unknown | Apatinib Treatment for Advanced Esophagus Cancer |
| NCT03542422 | — | P2 | unknown | Apatinib as First -Line Treatment for Advanced Esophagus Cancer |
Cervical Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03029013 | — | N/A | unknown | Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer |
| NCT03546855 | — | P2 | unknown | Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy. |
Brain Metastases (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03356600 | — | P2 | unknown | Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer |
| NCT01218529 | — | P2 | completed | Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors |
Malignant Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03383237 | — | P2 | unknown | Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma |
| NCT01264081 | — | P2 | terminated | Lapatinib in Stage IV Melanoma With ERBB4 Mutations |
Lung Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03376737 | — | P2 | unknown | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma |
| NCT02691871 | — | P1 | unknown | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR |
HER2 Positive Metastatic Breast Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03080805 | PHOEBE | P3 | unknown | Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) |
| NCT02422199 | — | P1/P2 | unknown | A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab |
Nasopharyngeal Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02874651 | ADVANCE | P2 | terminated | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy |
| NCT03180476 | — | P2 | completed | Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma |
Head and Neck Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02989259 | — | P2 | unknown | Apatinib for Advanced Non-squamous Head and Neck Cancer |
| NCT02943252 | — | P2 | unknown | The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer |
Adenoid Cystic Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02942693 | — | P2 | unknown | Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma |
| NCT02775370 | — | P2 | unknown | A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck |
Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02836171 | — | P1 | completed | Effect of Itraconazole on the Pharmacokinetics of Apatinib |
| NCT02836821 | — | P1 | completed | Effect of Rifampicin on the Pharmacokinetics of Apatinib |
Central Nervous System Metastases (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01783756 | — | P1/P2 | completed | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis |
| NCT00098605 | — | P2 | completed | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases |
Adenocarcinoma of the Gastroesophageal Junction (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01123473 | — | P2 | terminated | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer |
| NCT01705340 | — | P1 | terminated | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery |
Advanced Cancers (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01087983 | — | P1 | completed | Lapatinib With Sirolimus or Metformin |
| NCT01454804 | — | P1 | completed | Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors |
Solid Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00984425 | — | P1 | completed | The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors |
| NCT00495872 | — | P1 | completed | Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor |
Prostate Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00246753 | NRR | P2 | completed | Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy |
| NCT00953576 | KHLAD | P1/P2 | terminated | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer |
Lung Cancer, Non-Small Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00528281 | TYKERB | P1 | completed | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase |
| NCT00073008 | — | P2 | terminated | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer |
Carcinoma, Renal Cell (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00516672 | — | P1 | completed | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors |
| NCT00158782 | — | P1 | completed | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients |
Neoplasms, Head and Neck (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00387127 | — | P2 | completed | Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer |
| NCT00424255 | — | P3 | completed | Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery |
Estrogen Receptor Positive (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00118157 | — | P2 | completed | Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen |
| NCT00390455 | — | P3 | completed | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive |
Adult Primary Hepatocellular Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00107536 | — | P2 | completed | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer |
| NCT00101036 | — | P2 | completed | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery |
Recurrent Prostate Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00103194 | — | P2 | completed | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer |
| NCT00095667 | — | P2 | completed | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer |
Unresectable Hepatocellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07314372 | FAD-HCC-001 | P2 | not yet recruiting | FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma |
Hepatocellular Carcinomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07324473 | — | P2 | not yet recruiting | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study |
Hepato Cellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07267806 | — | P3 | recruiting | Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC |
Mixed Hepatocellular-cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07105748 | TASK-05 | P2 | recruiting | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) |
AFP Gastric or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06973330 | — | P2 | not yet recruiting | Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma |
Hepatocellular Carcinoma(HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06893887 | ICT-HCC | N/A | recruiting | Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma |
Adebrelimab (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07353684 | — | P2 | recruiting | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer |
Recurrent Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06769425 | HS-10502 | P1 | recruiting | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors |
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06925243 | — | P3 | recruiting | Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma |
Neoadjuvant Therapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06913777 | — | P3 | recruiting | Neoadjuvant SNF Precision Therapy Phase III |
Recurrent/Metastatic Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06771154 | A-CAPE | P2 | not yet recruiting | Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial |
Adrenal Cortical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06831175 | — | P2 | recruiting | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma |
Breast Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06889688 | — | P3 | recruiting | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer |
HCC - Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07157969 | — | P2 | recruiting | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC |
Advanced Esophageal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06745193 | — | P2 | not yet recruiting | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer |
Intrahepatic Cholangiocarcinoma (Icc) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06925516 | ACADEMY | P2 | recruiting | A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC |
Metastatic Pancreatic Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06759090 | — | P2 | not yet recruiting | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer |
Neuroendocrine Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06764368 | — | P2 | not yet recruiting | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors |
Dedifferentiated Liposarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06694324 | — | P2 | not yet recruiting | First-line Treatment of Advanced/unresectable DDLPS |
Limited-stage Small Cell Lung Cancer (LS-SCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06773156 | — | P2 | enrolling by invitation | Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer |
Liver Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06632522 | — | P2 | not yet recruiting | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . |
HER2-negative Breast Cancer Brain Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06418594 | — | P2 | recruiting | Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis |
Epithelial Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06539091 | — | P3 | not yet recruiting | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer |
Unresectable Locally Advanced Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06700421 | — | P2 | active not recruiting | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis |
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06351020 | — | P3 | active not recruiting | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. |
Small Cell Lung Cancer Limited Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06483282 | — | P2 | recruiting | A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer |
SCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06475209 | — | P2 | recruiting | Adebrelimab + Apatinib in SCLC Maintenance Therapy |
Fludzoparib" and Anti-angiogenic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06255392 | — | P3 | recruiting | Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer |
Gastric/Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06415669 | — | P2 | recruiting | A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma |
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06385873 | — | P2 | not yet recruiting | RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer |
Unresectable Biliary Tract Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06749730 | GP | P2 | recruiting | Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma |
Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06339619 | — | P2 | recruiting | Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma |
Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06280508 | — | P2 | recruiting | Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer |
Biliary Tract Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06181032 | — | P1 | recruiting | A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies |
Ovarian Cancer Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06102707 | — | N/A | not yet recruiting | The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients |
Chordoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06140732 | — | P2 | unknown | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma |
Digestive System Cancers (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06099821 | — | P2 | recruiting | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade |
Salivary Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06145308 | — | P2 | recruiting | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing |
Malignant Neoplasms of Digestive Organs (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05934331 | — | P2 | recruiting | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study |
BCLC Stage C Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06172205 | — | P3 | recruiting | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC |
HR+/HER2-breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05889871 | — | P3 | unknown | A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer |
Immunotherapy Gastrict Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05699655 | — | P2/P3 | recruiting | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer |
Macrotrabecular Massive Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05839197 | CCGLC-010 | P2 | unknown | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC |
Esophageal Cancer by AJCC V8 Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05738434 | — | P2 | recruiting | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC |
Locally Advanced Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05742750 | HP-BTC-001 | P1/P2 | completed | A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer |
Gastrointestinal Stromal Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05751733 | — | N/A | recruiting | Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST |
Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05653817 | — | N/A | unknown | Advanced or Metastatic Cholangiocarcinoma |
Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05942573 | — | P2 | unknown | Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial |
Advanced Biliary Tract Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05451290 | — | P2 | active not recruiting | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer |
Peripheral T Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05559008 | — | P1/P2 | unknown | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes |
Stage III Hepatocellular Cancer (CNLC Staging) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05412589 | — | P2 | recruiting | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC |
Gestational Trophoblastic Neoplasia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05139095 | — | P2 | recruiting | Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia |
Advanced or Metastatic EP-NEC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05142865 | — | P2 | unknown | Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas |
PD-1 Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05265793 | — | P2 | unknown | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma |
Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05223088 | — | P2 | completed | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer |
Advanced Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05019690 | — | P1/P2 | recruiting | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer |
Oral Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05069857 | — | P2 | recruiting | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients |
Sarcoma,Soft Tissue (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05235100 | SPARE-02 | P2 | completed | Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） |
Neuroblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05027386 | — | P1/P2 | recruiting | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. |
Stage IVB Cervical Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04974944 | — | P2 | unknown | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer |
Metastatic Castration Resistant Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04869488 | — | P2 | completed | A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer |
Advanced Non Squamous NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04670913 | — | P2 | unknown | Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy |
Recurrent Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05156970 | — | P2 | completed | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC |
Locally Advanced Thyroid Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06482086 | — | P2 | recruiting | Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer |
Hepatocellular Carcinoma Resectable (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04850040 | — | P2 | unknown | A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin |
Advanced Gastric Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04948125 | — | P2 | unknown | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma |
Hepatocellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04639180 | HCC | P3 | active not recruiting | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation |
Locally Advanced Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04749394 | — | P2 | unknown | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy |
Extensive Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05001412 | — | P1 | unknown | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC |
Resectable Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04701060 | — | P2 | completed | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma |
Advanced/Metastatic Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04665362 | — | P1 | unknown | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC |
Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04625803 | — | P2 | completed | Neoadjuvant Therapy for Locally Advanced Colon Cancer |
ICC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04682249 | — | P2 | withdrawn | Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC |
Recurrent Medulloblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04501718 | — | P2 | recruiting | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children |
Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04609293 | — | N/A | unknown | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma |
Radioactive Iodine-refractory Differentiated Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04560127 | — | P2 | active not recruiting | Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer |
Adenocarcinoma of the Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04459078 | — | P2 | unknown | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma |
Recurrent Atypical/malignant Meningioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04501705 | — | N/A | recruiting | Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults |
Lung Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04490421 | — | P3 | unknown | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. |
Lung Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04425135 | — | P2 | unknown | Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC |
Solid Tumor, Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04428086 | — | P1 | completed | A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. |
Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04476459 | — | P1/P2 | unknown | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL |
Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04296370 | — | P3 | unknown | A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation |
PD-L1 Positive Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04203485 | PD-L1 | P3 | unknown | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) |
Subjects With Impaired Renal Function and Healthy Subjects (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04414852 | — | P1 | unknown | A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function |
Oral Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04393506 | — | P1 | completed | Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma |
Locally Advanced Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03917966 | — | P2 | unknown | The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC |
Hepatic Metastasis of Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04202978 | — | P1/P2 | unknown | Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer |
Locally Advanced or Metastatic Gastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04572542 | — | P1/P2 | unknown | Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer |
High-grade Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04253873 | — | P2 | unknown | Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas |
Advanced Metastatic Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04089657 | ASGARD | P2 | unknown | Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens |
BCLC Stage B Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04204577 | — | P2 | unknown | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer |
Recurrent Platinum-resistant Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04068974 | — | P2 | unknown | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer |
Radiation Injuries (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04152681 | — | P2 | unknown | Effect and Safety of Apatinib on Radiation-Induced Brain Injury |
Colorectal Cancer Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04067986 | — | P1/P2 | unknown | Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer |
Gestational Trophoblastic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04047017 | GTN | P2 | completed | Camrelizumab Combined With Apatinib for Recurrent Resistant GTN |
NSCLC Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03777124 | — | P2 | terminated | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer |
Locally Advanced or Metastatic and Unresectable HCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03764293 | — | P3 | completed | A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC |
Gastric Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04267549 | — | P2 | unknown | Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer |
Thyroid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04180007 | APT-01 | P2 | unknown | Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers |
Breast Cancer Organoids (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03925233 | — | N/A | unknown | Breast Cancer Treatment Based on Organ-like Culture |
Gastrointestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05225844 | — | P2 | unknown | An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal |
Childhood Rhabdomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03868852 | — | P1/P2 | unknown | Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children |
Tumor, Solid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03491631 | — | P1 | unknown | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors |
Lung Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03725423 | — | P4 | unknown | Apatinib for Advanced Lung Squmamous Carcinoma |
Gastric Cancer With Positive Exfoliative Cancer Cells (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03718624 | — | P2 | unknown | A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells |
Lung Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03709953 | Spark-AL003 | P2 | unknown | Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma |
Advanced Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03662035 | ASPC | P2 | unknown | Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer |
Biliary Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03609489 | — | P2 | unknown | A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma |
Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03650738 | — | P2 | unknown | This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment |
Newly Diagnosed Peripheral T-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03631862 | — | P4 | unknown | Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
Gallbladder Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03702491 | — | P2 | unknown | Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma |
Triple-Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03243838 | LANCET | P2 | completed | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer |
HER2-positive Advanced Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04185649 | — | P3 | unknown | The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer |
Advanced Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03407976 | APPEASE | P1 | terminated | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies |
Soft Tissue and Bone Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03539172 | RASS | P2 | unknown | Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study |
Progression-free Survival;Progression-free Survival;Disease Control Rate; Safety (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03531931 | — | N/A | unknown | Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial |
Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03510416 | — | P2 | unknown | Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma |
Platinum-resistant Recurrent Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04348032 | APPROVE | P2 | unknown | Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer |
Stage IV Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03475589 | — | P4 | unknown | Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations |
Advanced Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03422445 | — | P2 | unknown | A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma |
Peritoneal Metastases From Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03349827 | — | N/A | terminated | HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer |
Progression-free Survival (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03359018 | APFAO | P2 | completed | Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma |
Recurrent Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04216550 | — | N/A | unknown | Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas |
Biliary Tract Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03427242 | — | P2 | unknown | Apatinib for Advanced Biliary Carcinoma |
Refractory or Metastatic Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03320629 | — | P2 | terminated | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma |
Non-small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03267654 | — | P2 | unknown | Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03567135 | — | N/A | unknown | Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma |
Two Different Treatment Methods (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03334591 | — | P2 | unknown | Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer |
Apatinib Combined (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03192735 | — | P2 | unknown | Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer |
Angiogenesis Inhibitors，Ovarian Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03262545 | — | P2 | unknown | Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer |
Cytochrome P450 Interaction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03245307 | — | P1 | unknown | A Study To Test The Effect Of Apatinib On P450 Enzymes |
Advanced Triple-Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03254654 | — | P2 | completed | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer |
Non-squamous Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03127319 | — | P2 | unknown | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases |
Refractory Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03199677 | — | P2 | unknown | A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer |
HER-2 Negatived Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03950141 | — | P2 | unknown | Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer |
Soft Tissue Sarcoma, Adult, Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03121846 | — | P2 | unknown | Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy |
Non-squamous Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03376191 | — | N/A | unknown | Apatinib in Advanced Non-squamous，NSCLC |
Advanced Primary Liver Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03092895 | — | P2 | completed | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC |
Osteosarcoma, Advanced (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03163381 | — | P2 | unknown | Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study. |
Apatinib in Maintenance Treatment (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03129698 | — | P2 | unknown | The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer |
Soft Tissue Sarcoma Adult (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03104335 | — | P2 | withdrawn | Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial |
Differentiated Thyroid Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03167385 | — | P2 | unknown | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma |
Progression Free Survival (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03100955 | — | P3 | unknown | A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer |
Extensive-stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03135977 | — | P2 | unknown | Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy |
Esophagus Cancer, Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03285906 | — | P2/P3 | unknown | An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric |
Chemotherapy Effect (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03229096 | — | P2 | unknown | Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer |
Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03030937 | — | P2 | unknown | Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA |
Malignant Ascites (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03020979 | — | P2 | unknown | A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites |
Recurrent and Metastatic Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03026881 | — | P1 | unknown | A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients |
Relapsed and Refractory (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03376958 | — | P4 | completed | Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma |
Differentiated Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03048877 | — | P3 | unknown | Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer |
Anaplastic Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02101905 | — | P1 | completed | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma |
Advanced Esophageal Squamous Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03193424 | — | P2 | unknown | Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03384511 | — | P4 | completed | The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. |
Nonsquamous Nonsmall Cell Neoplasm of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02852798 | — | N/A | unknown | Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC |
Malignant Neoplasm of Stomach Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02697838 | — | P2 | unknown | Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer |
High-grade Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02848794 | — | P1/P2 | unknown | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma |
Cholangiocarcinoma of the Extrahepatic Bile Duct (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02836847 | — | P2 | unknown | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
EGFR Tyrosine Kinase Inhibitors Plus VEGFR Inhibitors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02824458 | — | P3 | unknown | A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations |
Metastatic Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02774200 | — | P2 | unknown | A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients. |
Quality of Life (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02998242 | ARCAP | N/A | completed | Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer |
Pancreatic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02726854 | Apslpanc | P2 | unknown | Apatinib as Second-line Treatment of Advanced Pancreatic Cancer |
Efficacy and Safety (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03660761 | — | P2 | completed | Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors |
Anemia of Chronic Kidney Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02581124 | — | P1 | completed | Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease |
Adenocarcinoma of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02493582 | — | P2 | active not recruiting | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR |
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02426034 | — | P4 | completed | A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer |
HER2 Positive Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02362958 | — | P2 | completed | A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer |
HER2-positive Refractory Advanced Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02342587 | — | P2 | completed | Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer |
Metastatic Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02158507 | ABT-888 | N/A | completed | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer |
Metastatic Breast Cancer With Intracranial Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01934894 | — | P2 | terminated | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases |
Malignant Solid Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02029001 | MOST plus | P2 | recruiting | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
Carcinoma, Ductal, Breast (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01891357 | — | P2 | terminated | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer |
Metastatic Thyroid Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01947023 | — | P1 | active not recruiting | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery |
Male Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01868503 | — | P2 | terminated | Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer |
HER2-Positive Early Stage Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01827163 | — | P2 | completed | Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer |
HER2+ Metastatic Breast Cancer (MBC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01808573 | NALA | P3 | completed | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting |
Non-HPV Locally Advanced Head and Neck Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01711658 | TRYHARD | P2 | completed | TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. |
HER2 Positive Esophagogastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01769508 | — | P2 | terminated | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer |
HER2-Positive Breast Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01622868 | — | P2 | completed | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer |
Urothelial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01700010 | — | P2 | withdrawn | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer |
Reccurent/Metastatic Solid Tumor Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01771458 | SHIVA | P2 | completed | A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer |
HER2-positive Gastric Cancer Patients With Liver Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02015169 | — | P2 | completed | Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis |
Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01666431 | — | P2 | terminated | Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment |
Locally Advance Breast Cancer (LABC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01471847 | — | P1 | completed | A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab |
HER2-negative Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01619111 | DETECT III | P3 | completed | DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs |
HER2/Neu Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01434303 | — | P1 | completed | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only |
Epithelial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01427322 | — | Early P1 | terminated | Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease |
Adenocarcinoma of the Esophagus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01395537 | GEJ | P1/P2 | terminated | Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) |
Recurrent Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01382706 | — | P2 | terminated | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder |
ErbB2-Positive Stage I-III Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01309607 | — | P2 | unknown | Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer |
Recurrent Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01454479 | — | P1 | unknown | A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma |
Her2 Positive Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01495884 | — | P1/P2 | terminated | The Myocet/Lapatinib Study. ICORG 10-03, V5 |
Bladder Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01245660 | LAPAINBLAD | Early P1 | terminated | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy |
HER-2 Gene Amplification (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01304784 | — | P1 | completed | A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer |
Advanced or Metastatic Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01512745 | — | P3 | completed | Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer |
Estrogen Receptor Negative (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01281163 | — | P1 | terminated | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer |
GastroEsophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01145404 | GastroLap | P2 | terminated | Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer |
Non-Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01270386 | — | P2 | completed | A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer |
HER-2 Positive Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02131506 | CAELYX | P1 | terminated | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer |
BRMS1 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01050322 | GLICO-0801 | P2 | completed | Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. |
Neurofibromatosis 2 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00973739 | NF2 | P2 | completed | Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors |
Pancreas Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00881621 | — | P2 | terminated | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer |
Ductal Breast Carcinoma In Situ (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00555152 | — | N/A | completed | Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ |
Pituitary Adenomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00939523 | — | P2 | completed | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy |
Brain Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00883688 | — | P2 | completed | Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma |
Vestibular Schwannoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00863122 | — | Early P1 | completed | Concentration and Activity of Lapatinib in Vestibular Schwannomas |
Ductal Carcinoma in Situ (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00857714 | DCIS | N/A | terminated | Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast |
Metastases, Brain (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00820222 | HER2 | P3 | completed | Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer |
Male Breast Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00770809 | — | P3 | completed | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery |
Brain Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00826241 | — | P2 | completed | Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma |
HER2 Positive Breast Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00684983 | — | P2 | completed | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer |
Locally Advanced or Metastatic Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00634088 | HER2 | P1 | terminated | Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer |
Relapsed Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00479856 | — | P2 | terminated | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer |
Oesophagogastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00450203 | ST03 | P2/P3 | unknown | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer |
Neoplasms, Colorectal (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00536809 | — | P1 | completed | Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer |
Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00633490 | — | P1 | unknown | Study of Apatinib as an Inhibitor of Tumor Angiogenesis |
Invasive Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00486668 | — | P3 | unknown | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer |
Neoplasms, Uterine Cervix (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00430781 | — | P2 | completed | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer |
Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00352443 | — | P1 | completed | S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma |
Squamous Cell Carcinoma of Head and Neck (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00371566 | — | P2 | completed | A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer |
Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00259987 | GW572016 | P2 | completed | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus |
Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00239200 | GW572016 | P2 | terminated | Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus |
Ovarian Epithelial Cancer Stage III (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00316407 | — | P1/P2 | completed | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients |
Primary Peritoneal Cavity Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00113373 | — | P2 | completed | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer |
Recurrent Salivary Gland Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00114283 | — | P2 | completed | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer |
Brain and Central Nervous System Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00099060 | — | P1/P2 | completed | Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme |
Diffuse Adenocarcinoma of the Stomach (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00103324 | — | P2 | completed | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer |
Recurrent Endometrial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00096447 | — | P2 | completed | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer |
Metastatic Squamous Neck Cancer With Occult Primary (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00098631 | — | P2 | completed | Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer |
Recurrent Childhood Anaplastic Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00095940 | — | P1/P2 | completed | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors |
High-grade Salivary Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00095563 | — | P2 | completed | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers |
Apatinib pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| SOP-XH-IRB | NCT07314203 | P3 | not yet recruiting | Gastric Cancer | 118 | — |
| HCC | NCT04639180 | P3 | active not recruiting | Hepatocellular Carcinoma (HCC) | 687 | — |
| MULTISARC | NCT03784014 | P3 | completed | Soft Tissue Sarcoma | 603 | PMID 34740331 |
| EPHOS-B | NCT01104571 | P3 | unknown | Breast Cancer | 257 | — |
| TRIPLET-III | NCT05313282 | P3 | unknown | C-staged Hepatocellular Carcinoma in BCLC Classification | 140 | PMID 31070690 |
| HER2 | NCT00680901 | P3 | completed | Neoplasms, Gastrointestinal Tract | 545 | PMID 26628478 |
| SHR-1210 | NCT03813784 | P3 | completed | Gastric Cancer | 885 | PMID 41819560 |
| HER2 | NCT03084939 | P3 | completed | Breast Cancer | 351 | PMID 38751488 |
| TH V THL | NCT01526369 | P3 | completed | Metastatic Breast Cancer | 75 | — |
| PD-L1 | NCT04203485 | P3 | unknown | PD-L1 Positive Non-small Cell Lung Cancer | 762 | PMID 33323401 |
| DETECT III | NCT01619111 | P3 | completed | HER2-negative Metastatic Breast Cancer | 105 | PMID 38175595 |
| ALTTO | NCT00490139 | P3 | completed | Neoplasms, Breast | 8,381 | PMID 33152119 |
| PHOEBE | NCT03080805 | P3 | unknown | HER2 Positive Metastatic Breast Cancer | 240 | PMID 33581774 |
| AFLC | NCT03428022 | P3 | unknown | NSCLC | 54 | — |
| Neo ALTTO | NCT00553358 | P3 | completed | Neoplasms, Breast | 455 | PMID 22785351 |
| NALA | NCT01808573 | P3 | completed | HER2+ Metastatic Breast Cancer (MBC) | 621 | PMID 32678716 |
| AHELP | NCT02329860 | P3 | completed | Carcinoma, Hepatocellular | 400 | PMID 33971141 |
| HER2 | NCT00820222 | P3 | completed | Metastases, Brain | 540 | PMID 25605838 |
| GW572016 | NCT00073528 | P3 | completed | Breast Neoplasms | 1,286 | PMID 29522361 |
| ANSWER | NCT02332512 | P3 | unknown | Carcinoma, Non-Small-Cell Lung | 417 | — |
| OVER | NCT02394496 | P3 | unknown | Metastatic Breast Cancer | 396 | PMID 11252954 |
| GeparQuinto | NCT00567554 | P3 | completed | Breast Cancer | 2,600 | PMID 25223482 |
| EMILIA | NCT00829166 | P3 | completed | Breast Cancer | 991 | PMID 23020162 |
| TEACH | NCT00374322 | P3 | completed | Neoplasms, Breast | 3,166 | PMID 24687830 |
| XELODA | NCT00078572 | P3 | completed | Breast Cancer | 408 | PMID 18188694 |
| APP | NCT03982485 | P2 | active not recruiting | Breast Cancer | 196 | — |
| FASCINATE-N | NCT05582499 | P2 | recruiting | Breast Neoplasm | 716 | PMID 38362377 |
| A-CAPE | NCT06771154 | P2 | not yet recruiting | Recurrent/Metastatic Endometrial Cancer | 140 | — |
| FAD-HCC-001 | NCT07314372 | P2 | not yet recruiting | Unresectable Hepatocellular Carcinoma (HCC) | 86 | PMID 39300923 |
| ACADEMY | NCT06925516 | P2 | recruiting | Intrahepatic Cholangiocarcinoma (Icc) | 38 | — |
| TASK-05 | NCT07105748 | P2 | recruiting | Mixed Hepatocellular-cholangiocarcinoma | 45 | — |
| LIAES | NCT06749691 | P2 | recruiting | Small Cell Lung Cancer Extensive Stage | 30 | — |
| MOST plus | NCT02029001 | P2 | recruiting | Malignant Solid Neoplasms | 900 | PMID 37444551 |
| BIOVAS | NCT04072042 | P2 | recruiting | Sarcoma | 30 | — |
| GP | NCT06749730 | P2 | recruiting | Unresectable Biliary Tract Carcinoma | 63 | — |
| APPEAL | NCT03164694 | P2 | withdrawn | Lung Cancer | 0 | — |
| TNBC | NCT05447702 | P2 | recruiting | Triple Negative Breast Cancer | 35 | — |
| AIEO | NCT04824352 | P2 | suspended | Effect of Drug | 44 | — |
| HELEX | NCT00999804 | P2 | active not recruiting | Breast Cancer | 128 | PMID 31662331 |
| TRIPLET | NCT04191889 | P2 | unknown | C-staged Hepatocellular Carcinoma in BCLC Classification | 47 | PMID 29471013 |
| AK104 | NCT05853172 | P2 | unknown | Gastric Cancer | 30 | — |
| ROME | NCT04591431 | P2 | unknown | Breast Cancer | 400 | PMID 41963505 |
| CCGLC-010 | NCT05839197 | P2 | unknown | Macrotrabecular Massive Hepatocellular Carcinoma | 38 | — |
| HNSCC | NCT05189184 | P2 | unknown | Head and Neck Squamous Cell Carcinoma | 30 | — |
| SHR-1210 | NCT04609176 | P2 | unknown | Gastric Cancer | 64 | PMID 40082418 |
| XHZL | NCT03193814 | P2 | withdrawn | Colorectal Cancer | 0 | — |
| C-couple | NCT04724226 | P2 | unknown | Hepatocellular Carcinoma | 34 | — |
| SPARE-02 | NCT05235100 | P2 | completed | Sarcoma,Soft Tissue | 30 | — |
| CAPT | NCT04930315 | P2 | unknown | Hepatocellular Carcinoma | 78 | — |
| RENMIN-213 | NCT06238752 | P2 | completed | Advanced Gastric Adenocarcinoma | 33 | — |
| IMplus | NCT04440917 | P2 | unknown | Head and Neck Squamous Cell Carcinoma | 32 | — |
| PROACH | NCT03742193 | P2 | unknown | Osteosarcoma | 43 | — |
| OAIE | NCT05277480 | P2 | completed | Effect of Drug | 81 | — |
| SABRE | NCT04878107 | P2 | unknown | Non-Small Cell Lung Cancer | 88 | — |
| CAMERA | NCT04901754 | P2 | unknown | Small Cell Lung Carcinoma | 38 | — |
| CCWSA/OAFLAG | NCT04792515 | P2 | unknown | Locally Advanced Gastric Cancer | 67 | — |
| MAPAC | NCT04351308 | P2 | unknown | Osteosarcoma | 60 | — |
| ABST-C | NCT03271255 | P2 | unknown | Colorectal Neoplasms | 80 | PMID 22949147 |
| Poetry-1 | NCT02976896 | P2 | completed | Esophageal Squamous Cell Carcinoma | 43 | — |
| TRYHARD | NCT01711658 | P2 | completed | Non-HPV Locally Advanced Head and Neck Cancer | 142 | PMID 37768670 |
| APPROVE | NCT04348032 | P2 | unknown | Platinum-resistant Recurrent Ovarian Cancer | 152 | PMID 35771546 |
| NSCLC | NCT03083041 | P2 | completed | Carcinoma, Non-Small-Cell Lung | 210 | PMID 35832447 |
| LANCET | NCT03243838 | P2 | completed | Triple-Negative Breast Cancer | 31 | PMID 35983024 |
| ASGARD | NCT04089657 | P2 | unknown | Advanced Metastatic Gastric Cancer | 40 | — |
| HCC-009 | NCT04297202 | P2 | unknown | Hepatocellular Carcinoma | 20 | PMID 35379737 |
| PASSION | NCT03417895 | P2 | completed | Small-cell Lung Cancer | 59 | PMID 33166719 |
| GTN | NCT04047017 | P2 | completed | Gestational Trophoblastic Disease | 20 | PMID 34624252 |
| Spark-AL003 | NCT03709953 | P2 | unknown | Lung Carcinoma | 33 | PMID 28367065 |
| RESCUE | NCT03463876 | P2 | completed | Hepatocellular Carcinoma | 190 | PMID 36852452 |
| HZ-T-PD1-APA | NCT03793725 | P2 | unknown | Hepatocellular Carcinoma | 30 | — |
| ACABC | NCT04642664 | P2 | completed | Biliary Tract Cancer | 22 | PMID 33087333 |
| NSCLC | NCT03811054 | P2 | unknown | Non Small Cell Lung Cancer | 60 | — |
| SHR-1210 | NCT04014101 | P2 | unknown | Hepatocellular Carcinoma | 40 | — |
| CABC006 | NCT02878057 | P2 | completed | Breast Cancer | 30 | PMID 1701519 |
| MK 01 | NCT03547804 | P2 | completed | Small-cell Lung Cancer | 31 | PMID 29261000 |
| ADVANCE | NCT02874651 | P2 | terminated | Nasopharyngeal Neoplasms | 25 | — |
| ASPC | NCT03662035 | P2 | unknown | Advanced Pancreatic Cancer | 30 | — |
| NPC | NCT03213587 | P2 | unknown | Nasopharyngeal Carcinoma | 51 | — |
| XQonc-007 | NCT03190239 | P2 | withdrawn | Advanced Non-squamous Non-small-cell Lung Cancer | 0 | — |
| APT-01 | NCT04180007 | P2 | unknown | Thyroid | 10 | PMID 35767182 |
| RASS | NCT03539172 | P2 | unknown | Soft Tissue and Bone Tumor | 61 | — |
| APFAO | NCT03359018 | P2 | completed | Progression-free Survival | 43 | PMID 32021426 |
| NSCLC | NCT03416231 | P2 | unknown | NSCLC | 20 | PMID 31261514 |
| HERACLES | NCT03225937 | P2 | unknown | Metastatic Colorectal Cancer | 54 | PMID 27108243 |
| AHEAD-301 | NCT02596256 | P2 | unknown | Gastric Cancer | 80 | — |
| TEAL | NCT02073487 | P2 | completed | Breast Cancer | 32 | PMID 31477168 |
| HCC | NCT03046979 | P2 | unknown | Hepatocellular Carcinoma | 30 | PMID 33145266 |
| EASE | NCT03129256 | P2 | completed | Non-small Cell Lung Cancer | 52 | — |
| SCLC | NCT02995187 | P2 | unknown | Small Cell Lung Cancer | 25 | PMID 32250517 |
| TCHL Phase II | NCT01485926 | P2 | completed | Breast Cancer | 120 | PMID 28750640 |
| OECTAPGAMPC | NCT02863367 | P2 | unknown | Metastatic Pancreatic Cancer | 30 | — |
| Apslpanc | NCT02726854 | P2 | unknown | Pancreatic Neoplasms | 30 | — |
| PAMELA | NCT01973660 | P2 | completed | Breast Cancer | 151 | PMID 29045543 |
| LV | NCT01730677 | P2 | unknown | Metastatic Breast Cancer | 150 | PMID 31690831 |
| SHIVA | NCT01771458 | P2 | completed | Reccurent/Metastatic Solid Tumor Disease | 742 | PMID 27993804 |
| VITAL | NCT01013740 | P2 | completed | Cancer | 112 | PMID 26384789 |
| THOR | NCT01985893 | P2 | withdrawn | Metastatic Breast Cancer | 0 | — |
| E-VITA | NCT01534455 | P2 | terminated | Metastatic Breast Cancer | 43 | — |
| Neo-All-In | NCT01275859 | P2 | completed | Breast Cancer | 25 | — |
| GERICO09 | NCT01262469 | P2 | completed | Metastatic Breast Cancer | 4 | — |
| GastroLap | NCT01145404 | P2 | terminated | GastroEsophageal Cancer | 76 | PMID 25694417 |
| HCC | NCT01192971 | P2 | completed | Advanced Hepatocellular Carcinoma | 121 | — |
| NRR | NCT00246753 | P2 | completed | Prostate Cancer | 29 | — |
| NF2 | NCT00973739 | P2 | completed | Neurofibromatosis 2 | 21 | — |
| CHERLOB | NCT00429299 | P2 | completed | Neoplasms, Breast | 121 | PMID 24590635 |
| ELBA | NCT01005641 | P2 | withdrawn | Breast Cancer | 0 | — |
| GW | NCT00206427 | P2 | completed | Breast Cancer | 49 | — |
| HERLAP | NCT00842998 | P2 | unknown | Metastatic Breast Cancer | 120 | — |
| GLICO-0801 | NCT01050322 | P2 | completed | BRMS1 | 142 | PMID 34037241 |
| MAPLE | NCT00299286 | P2 | completed | Breast Cancer | 121 | — |
| ELATE | NCT01205217 | P2 | withdrawn | Neoplasms, Breast | 0 | — |
| VEG102857 | NCT00350727 | P2 | completed | Glioma | 75 | — |
| APRiCOT-B | NCT00657137 | P2 | terminated | Breast Cancer | 12 | — |
| TOPO-LAPA | NCT00888810 | P2 | terminated | Cancer | 39 | — |
| GW572016 | NCT00239200 | P2 | terminated | Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus | 29 | — |
| GW572016 | NCT00259987 | P2 | completed | Adenocarcinoma | 24 | — |
| GW572016 | NCT00044343 | P2 | completed | Colorectal Cancer | 80 | — |
Terminated and withdrawn Apatinib trials (91)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT03164694withdrawnAPatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC
- NCT03743428suspendedBiomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)
- NCT04824352suspendedApatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma
- NCT03193814withdrawnSafety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer
- NCT04863430withdrawnApatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach
- NCT03777124terminatedPhase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer
- NCT04335006terminatedA Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.
- NCT03228043withdrawnApatinib for Resectable Colorectal Cancer
- NCT00251433terminatedGW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
- NCT03792503withdrawnPemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen
- NCT03787251withdrawnA Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib
- NCT03711279terminatedA Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
- NCT03251417terminatedApatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
- NCT01873833terminatedCapecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
- NCT04682249withdrawnSystemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC
- NCT02874651terminatedADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
- NCT03190239withdrawnEfficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients
- NCT03407976terminatedApatinib With Pembrolizumab in Previously Treated Advanced Malignancies
- NCT00508274terminatedLapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China
- NCT03587129terminatedClinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
- NCT02213042terminatedEvaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
- NCT03349827terminatedHIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer
- NCT03104335withdrawnApatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial
- NCT00272987terminatedErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib
- NCT03256721terminatedCompare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC
- NCT01700010withdrawnTrial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer
- NCT03320629terminatedA Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
- NCT00759642terminatedLapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
- NCT01137994withdrawnA Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
- NCT00968968terminatedContinued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
- NCT01190241terminatedTargeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study
- NCT01382706terminatedDocetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
- NCT02294786terminatedStudy of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer
- NCT01589861terminatedSafety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer
- NCT01934894terminatedCabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
- NCT00496366terminatedCapecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
- NCT01499160terminatedLetrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
- NCT01891357terminatedPhase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
- NCT00490061terminatedLapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
- NCT01557764withdrawnLapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer
- NCT02131506terminatedA Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
- NCT01497626terminatedLapatinib and Bortezomib in Patients With Advanced Malignancies
- NCT01868503terminatedLapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
- NCT01427322terminatedRandomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease
- NCT01985893withdrawnSafety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
- NCT01534455terminatedEfficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA)
- NCT01769508terminatedStudy of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
- NCT01395537terminatedLapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
- NCT01495884terminatedThe Myocet/Lapatinib Study. ICORG 10-03, V5
- NCT01658358terminatedErbB2 Positive Metastatic Breast Cancer
- NCT01123473terminatedEpirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
- NCT01238029terminatedDose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer
- NCT01161368terminatedA Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
- NCT01272141terminatedA Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
- NCT01477060terminatedModulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer
- NCT01281163terminatedLapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
- NCT01666431terminatedSingle-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment
- NCT01264081terminatedLapatinib in Stage IV Melanoma With ERBB4 Mutations
- NCT01145404terminatedTrial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer
- NCT00756470terminatedPhase II Neoadjuvant in Inflammatory Breast Cancer
- NCT00881621terminatedLapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
- NCT00953576terminatedKetoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer
- NCT01199367terminatedSafety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer
- NCT01118975terminatedGCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
- NCT01705340terminatedAkt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
- NCT00903656terminatedLapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy
- NCT00709618terminatedLapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
- NCT01005641withdrawnELBA: Exemestane and Lapatinib in Advanced Breast Cancer
- NCT00963547terminatedA Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015)
- NCT01245660terminatedA Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy
- NCT00225758terminatedLapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
- NCT00804310terminatedLapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
- NCT00820924terminatedStudy of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells
- NCT00754702terminatedVinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer
- NCT00682279withdrawnA Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors
- NCT01205217withdrawnLapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer
- NCT00499681terminatedPhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
- NCT00857714terminatedLapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast
- NCT00634088terminatedPhase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
- NCT00479856terminatedLapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
- NCT00437073terminatedBrain Metastases In ErbB2-Positive Breast Cancer
- NCT00343759withdrawnPresurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy
- NCT00657137terminatedAPRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202)
- NCT00447226terminatedRandomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists
- NCT00447122terminatedBrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
- NCT00898573withdrawnLapatinib Resistance in Patients With Breast Cancer
- NCT00073008terminatedA Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
- NCT00513253withdrawnA Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib
- NCT00888810terminatedEfficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer
- NCT00239200terminatedLapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus
- NCT00317434terminatedMaximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer
All Apatinib trials (787)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | P1/P2 | active not recruiting | 192 | CARsgen Therapeutics Co., Ltd. | Oct 2020 | |
| NCT04803539 | Artemis | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | P2/P3 | recruiting | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Apr 2021 |
| NCT02493582 | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | P2 | active not recruiting | 400 | The First People's Hospital of Changzhou | Jul 2015 | |
| NCT02485015 | The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer | P2 | active not recruiting | 80 | The First People's Hospital of Changzhou | Jun 2015 | |
| NCT07267806 | Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC | P3 | recruiting | 326 | Linhui Peng | Oct 2025 | |
| NCT06831175 | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma | P2 | recruiting | 28 | West China Hospital | Mar 2025 | |
| NCT06576973 | Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | P2 | recruiting | 35 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aug 2024 | |
| NCT06255392 | Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | P3 | recruiting | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jun 2024 | |
| NCT07371910 | Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer | P3 | active not recruiting | 200 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jun 2024 | |
| NCT03982485 | APP | Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer | P2 | active not recruiting | 196 | RenJi Hospital | Oct 2018 |
| NCT06925243 | Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma | P3 | recruiting | 682 | Zuoyi Jiao | Apr 2025 | |
| NCT06773156 | Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer | P2 | enrolling by invitation | 37 | Second Affiliated Hospital of Nanchang University | Nov 2024 | |
| NCT07464756 | SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer | P2 | not yet recruiting | 80 | The First Affiliated Hospital with Nanjing Medical University | Apr 2026 | |
| NCT07309419 | Cocktail-001 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | P2/P3 | not yet recruiting | 222 | Shanghai Zhongshan Hospital | Dec 2025 |
| NCT07026149 | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer | P2 | recruiting | 30 | Ruijin Hospital | Jun 2025 | |
| NCT06881017 | Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping | P2 | not yet recruiting | 140 | China Medical University, China | May 2025 | |
| NCT05582499 | FASCINATE-N | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | P2 | recruiting | 716 | Fudan University | Nov 2022 |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | P3 | recruiting | 262 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jul 2023 | |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | P3 | recruiting | 246 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Feb 2025 | |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | P3 | recruiting | 164 | XIANG YANQUN | May 2024 | |
| NCT06771154 | A-CAPE | Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial | P2 | not yet recruiting | 140 | Peking Union Medical College Hospital | Apr 2025 |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | P2 | recruiting | 20 | Lei ZHAO | Mar 2024 | |
| NCT06181032 | A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies | P1 | recruiting | 35 | First Affiliated Hospital of Fujian Medical University | Dec 2023 | |
| NCT06447623 | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer | P3 | recruiting | 184 | Fudan University | Feb 2024 | |
| NCT07324473 | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study | P2 | not yet recruiting | 65 | First Affiliated Hospital of Chongqing Medical University | Jan 2026 | |
| NCT07314372 | FAD-HCC-001 | FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma | P2 | not yet recruiting | 86 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Feb 2026 |
| NCT07371871 | TAS-102 | A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer | N/A | not yet recruiting | 30 | Anhui Provincial Cancer Hospital | Jan 2026 |
| NCT07569679 | Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer | P2 | recruiting | 124 | Air Force Military Medical University, China | Dec 2025 | |
| NCT07135544 | A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer | P2 | recruiting | 37 | Yongjun Chen | Aug 2025 | |
| NCT07357532 | Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD | P2 | not yet recruiting | 44 | Peking University Cancer Hospital & Institute | Jan 2026 | |
| NCT06925516 | ACADEMY | A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC | P2 | recruiting | 38 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Apr 2025 |
| NCT06786312 | A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer | P2 | not yet recruiting | 34 | Fujian Cancer Hospital | Jan 2025 | |
| NCT06339619 | Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma | P2 | recruiting | 32 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Mar 2024 | |
| NCT07314203 | SOP-XH-IRB | Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer | P3 | not yet recruiting | 118 | Fujian Medical University | Dec 2026 |
| NCT07105748 | TASK-05 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) | P2 | recruiting | 45 | Fudan University | Aug 2025 |
| NCT07294664 | PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer | P2 | recruiting | 78 | The First Affiliated Hospital of Zhengzhou University | Jun 2025 | |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | P2 | recruiting | 39 | Peking Union Medical College | Aug 2023 | |
| NCT05934331 | A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study | P2 | recruiting | 276 | LaNova Medicines Zhejiang Co., Ltd. | Jul 2023 | |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | P3 | recruiting | 101 | Guohui Xu | Aug 2024 | |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | P2 | recruiting | 46 | Shanghai Jiao Tong University School of Medicine | Sep 2021 | |
| NCT06759090 | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | P2 | not yet recruiting | 43 | Zhejiang University | Jan 2025 | |
| NCT07033819 | Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib | P2 | recruiting | 48 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jun 2025 | |
| NCT06764368 | Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors | P2 | not yet recruiting | 39 | Beijing Chest Hospital | Jan 2025 | |
| NCT07236528 | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | P2 | not yet recruiting | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Nov 2025 | |
| NCT07353684 | Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer | P2 | recruiting | 49 | Beijing Friendship Hospital | May 2025 | |
| NCT06385873 | RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer | P2 | not yet recruiting | 32 | The First Affiliated Hospital with Nanjing Medical University | May 2024 | |
| NCT06280508 | Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer | P2 | recruiting | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Mar 2024 | |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | P2 | recruiting | 111 | Peking University Cancer Hospital & Institute | Jan 2024 | |
| NCT06893887 | ICT-HCC | Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma | N/A | recruiting | 300 | Nanjing Tianyinshan Hospital | May 2025 |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | P2 | not yet recruiting | 63 | Peking University | Feb 2025 | |
| NCT06607107 | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria | P2 | recruiting | 29 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Feb 2024 | |
| NCT07479732 | Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | P1/P2 | recruiting | 56 | Peking University People's Hospital | Mar 2026 | |
| NCT06538935 | SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma | P2 | not yet recruiting | 80 | Fujian Cancer Hospital | Jan 2025 | |
| NCT06749691 | LIAES | Liposomal Irinotecan and Apatinib in ES-SCLC | P2 | recruiting | 30 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Dec 2024 |
| NCT06693128 | Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer | P2 | active not recruiting | 80 | Ruijin Hospital | Nov 2024 | |
| NCT04208347 | Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer | P2/P3 | active not recruiting | 580 | Ruijin Hospital | Dec 2019 | |
| NCT07334483 | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC | P2 | recruiting | 120 | GrandPharma (China) Co., Ltd. | Aug 2025 | |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | P3 | recruiting | 244 | Sun Yat-sen University | May 2023 | |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | P3 | recruiting | 130 | The First Affiliated Hospital with Nanjing Medical University | Jan 2023 | |
| NCT02029001 | MOST plus | Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment | P2 | recruiting | 900 | Centre Leon Berard | Mar 2014 |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | P2 | not yet recruiting | 203 | Fujian Medical University | Sep 2022 | |
| NCT04072042 | BIOVAS | BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma | P2 | recruiting | 30 | Ruijin Hospital | Oct 2019 |
| NCT06607770 | Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers | P1/P2 | recruiting | 20 | Zhou Chengzhi | Sep 2024 | |
| NCT06537505 | A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors | P2 | not yet recruiting | 60 | Beidahuang Industry Group General Hospital | Aug 2024 | |
| NCT07192848 | Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy | P2 | not yet recruiting | 47 | Song Peng | Sep 2025 | |
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | P2 | recruiting | 300 | Peking Union Medical College Hospital | Feb 2025 | |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | P2 | recruiting | 30 | Qilu Hospital of Shandong University | Jul 2024 | |
| NCT06749730 | GP | Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma | P2 | recruiting | 63 | Henan Cancer Hospital | Apr 2024 |
| NCT05759572 | Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer | P2 | recruiting | 145 | Fudan University | Feb 2023 | |
| NCT03164694 | APPEAL | APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC | P2 | withdrawn | 0 | Sun Yat-sen University | May 2017 |
| NCT06415669 | A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma | P2 | recruiting | 30 | The First Affiliated Hospital of Xiamen University | May 2024 | |
| NCT01947023 | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | P1 | active not recruiting | 23 | National Cancer Institute (NCI) | Sep 2013 | |
| NCT06973330 | Sintilimab Plus Apatinib and SOX as First-line Treatment in Patients With AFP Gastric or Gastroesophageal Junction Adenocarcinoma | P2 | not yet recruiting | 40 | Anhui Provincial Cancer Hospital | Jul 2025 | |
| NCT06792162 | PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer | P2 | recruiting | 20 | Peking University Third Hospital | Apr 2023 | |
| NCT06913777 | Neoadjuvant SNF Precision Therapy Phase III | P3 | recruiting | 404 | Fudan University | Apr 2025 | |
| NCT05699655 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | P2/P3 | recruiting | 130 | Fujian Cancer Hospital | May 2023 | |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | P2 | recruiting | 188 | The First Affiliated Hospital of Zhengzhou University | Mar 2023 | |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | P3 | recruiting | 140 | Peking University Cancer Hospital & Institute | Mar 2023 | |
| NCT07031154 | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | P2 | not yet recruiting | 43 | The First Affiliated Hospital of Xiamen University | Jun 2025 | |
| NCT05751733 | Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | N/A | recruiting | 258 | Xiangya Hospital of Central South University | Feb 2023 | |
| NCT05139095 | Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia | P2 | recruiting | 70 | Peking Union Medical College Hospital | Jan 2022 | |
| NCT06418594 | Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis | P2 | recruiting | 30 | Beijing 302 Hospital | Oct 2024 | |
| NCT06700421 | Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis | P2 | active not recruiting | 32 | Wei Zhou | Aug 2024 | |
| NCT06483282 | A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer | P2 | recruiting | 38 | Jin Ying | Jun 2024 | |
| NCT06339281 | A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer | P2 | not yet recruiting | 68 | Li Huiping | May 2024 | |
| NCT06099821 | KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade | P2 | recruiting | 39 | Peking University Cancer Hospital & Institute | Oct 2023 | |
| NCT05447702 | TNBC | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | P2 | recruiting | 35 | West China Hospital | Nov 2022 |
| NCT04331093 | Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma | P2 | recruiting | 40 | Di Wu | Mar 2021 | |
| NCT03743428 | BABST-C | Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C) | N/A | suspended | 40 | Shenzhen People's Hospital | Oct 2020 |
| NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | P2 | not yet recruiting | 46 | Beijing Tsinghua Chang Gung Hospital | Oct 2024 | |
| NCT06081595 | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | P2 | not yet recruiting | 54 | Jin Li | Oct 2023 | |
| NCT06475209 | Adebrelimab + Apatinib in SCLC Maintenance Therapy | P2 | recruiting | 60 | Tang-Du Hospital | Jun 2024 | |
| NCT06351020 | LM-302 for the Treatment of Subjects With Claudin18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma. | P3 | active not recruiting | 387 | LaNova Medicines Zhejiang Co., Ltd. | Jun 2024 | |
| NCT05451290 | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer | P2 | active not recruiting | 30 | First Affiliated Hospital of Zhejiang University | Nov 2022 | |
| NCT06188455 | Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer | P3 | not yet recruiting | 37 | The First Affiliated Hospital of Xiamen University | Dec 2024 | |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | P2 | not yet recruiting | 49 | Fudan University | Dec 2024 | |
| NCT06281886 | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma | P2 | active not recruiting | 170 | Sun Yat-sen University | Dec 2023 | |
| NCT05594095 | SNF Platform Study of HR+/ HER2-advanced Breast Cancer | P2 | recruiting | 620 | Fudan University | Dec 2022 | |
| NCT06339216 | A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer. | P2 | not yet recruiting | 30 | Chinese PLA General Hospital | Mar 2024 | |
| NCT06102707 | The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients | N/A | not yet recruiting | 50 | Qilu Hospital of Shandong University | Nov 2023 | |
| NCT06485271 | A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer | — | recruiting | 504 | Changzhi People's Hospital Affiliated to Changzhi Medical College | Nov 2023 | |
| NCT06346392 | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | P3 | active not recruiting | 592 | AstraZeneca | Mar 2024 | |
| NCT06539091 | Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer | P3 | not yet recruiting | 51 | Anhui Provincial Hospital | Oct 2024 | |
| NCT06592287 | The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer | P1/P2 | not yet recruiting | 66 | Xianglin Yuan | Sep 2024 | |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | P2 | not yet recruiting | 38 | Zhujiang Hospital | Aug 2024 | |
| NCT05479487 | Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment | P2 | not yet recruiting | 132 | Xiaohua Wu MD | Aug 2022 | |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | P3 | recruiting | 550 | Jiangsu HengRui Medicine Co., Ltd. | Sep 2020 | |
| NCT06769425 | HS-10502 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors | P1 | recruiting | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | May 2025 |
| NCT06480864 | Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer | N/A | recruiting | 38 | Yunpeng Liu | Aug 2024 | |
| NCT06464614 | Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC. | P2 | not yet recruiting | 54 | The First Affiliated Hospital of Henan University of Science and Technology | Jul 2024 | |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | P2 | recruiting | 35 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jun 2022 | |
| NCT04639180 | HCC | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | P3 | active not recruiting | 687 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2021 |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | P3 | active not recruiting | 423 | Jiangsu HengRui Medicine Co., Ltd. | Aug 2022 | |
| NCT05198609 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | P3 | active not recruiting | 214 | Sun Yat-sen University | Jan 2022 | |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | P2 | recruiting | 33 | Yongyi Zeng | Apr 2024 | |
| NCT06313983 | A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer | P3 | recruiting | 339 | Tianjin Hemay Pharmaceutical Co., Ltd | Jan 2022 | |
| NCT04831528 | Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study | — | not yet recruiting | 100 | Fudan University | Apr 2021 | |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | P1/P2 | unknown | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jul 2023 | |
| NCT05889871 | A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer | P3 | unknown | 916 | Fudan University | Jun 2023 | |
| NCT05742750 | HP-BTC-001 | A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer | P1/P2 | completed | 48 | Sun Yat-sen University | Apr 2023 |
| NCT01273610 | Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer | P2 | active not recruiting | 40 | City of Hope Medical Center | Apr 2011 | |
| NCT06429696 | PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer | P2 | recruiting | 40 | Nanfang Hospital, Southern Medical University | Jul 2024 | |
| NCT04834674 | DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma | P2 | completed | 20 | Sichuan Cancer Hospital and Research Institute | Jul 2024 | |
| NCT04824352 | AIEO | Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma | P2 | suspended | 44 | Peking University People's Hospital | Apr 2021 |
| NCT04521153 | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | P2/P3 | active not recruiting | 294 | Shanghai Zhongshan Hospital | Mar 2021 | |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. | P1/P2 | recruiting | 125 | Sun Yat-sen University | Aug 2021 | |
| NCT06482008 | HAIC Combined With Adebrelimab Plus Apatinib as the First-line Treatment for HCC in BCLC Stage C: An Open-label, Single-arm, Phase II Study | P2 | not yet recruiting | 33 | Sun Yat-sen University | Jun 2024 | |
| NCT06140732 | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma | P2 | unknown | 30 | Xuanwu Hospital, Beijing | Oct 2023 | |
| NCT05653817 | Advanced or Metastatic Cholangiocarcinoma | N/A | unknown | 60 | First Affiliated Hospital Xi'an Jiaotong University | Jan 2023 | |
| NCT04559607 | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | N/A | unknown | 188 | Zhongda Hospital | Sep 2020 | |
| NCT00999804 | HELEX | Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | P2 | active not recruiting | 128 | Baylor Breast Care Center | Oct 2011 |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | P1/P2 | unknown | 116 | Ruijin Hospital | Sep 2022 | |
| NCT03784014 | MULTISARC | Molecular Profiling of Advanced Soft-tissue Sarcomas | P3 | completed | 603 | Institut National de la Santé Et de la Recherche Médicale, France | Oct 2019 |
| NCT06161272 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | P2 | unknown | 80 | Guangxi Medical University | Dec 2023 | |
| NCT06125171 | Tucidinostat Plus Apatinib for Advanced Osteosarcoma | P2 | unknown | 46 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Jan 2024 | |
| NCT05932264 | Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer | P2 | unknown | 60 | Sun Yat-sen University | Jul 2023 | |
| NCT04560127 | Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer | P2 | active not recruiting | 20 | Peking Union Medical College Hospital | Sep 2020 | |
| NCT04191889 | TRIPLET | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | P2 | unknown | 47 | Sun Yat-sen University | Apr 2020 |
| NCT04506242 | Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer | P2 | unknown | 74 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Sep 2020 | |
| NCT05713994 | CCGLC-001 | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | recruiting | 300 | Ze-yang Ding, MD | May 2020 |
| NCT03736863 | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | P2 | recruiting | 147 | The First Affiliated Hospital of Zhengzhou University | Dec 2019 | |
| NCT03523585 | DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | P3 | completed | 608 | Daiichi Sankyo | Aug 2018 | |
| NCT05853172 | AK104 | Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer | P2 | unknown | 30 | Tianjin Medical University Cancer Institute and Hospital | Mar 2023 |
| NCT03355612 | XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma | P3 | unknown | 456 | Tianjin Medical University Cancer Institute and Hospital | Dec 2017 | |
| NCT05192798 | Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | P2 | recruiting | 128 | The First Affiliated Hospital of Bengbu Medical University | Jan 2022 | |
| NCT06482086 | Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer | P2 | recruiting | 75 | West China Hospital | Jun 2021 | |
| NCT01104571 | EPHOS-B | Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer | P3 | unknown | 257 | Institute of Cancer Research, United Kingdom | Apr 2010 |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | P2 | unknown | 84 | Sun Yat-sen University | Oct 2022 | |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | P2 | unknown | 35 | Zhou Fuxiang | May 2021 | |
| NCT04501718 | Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children | P2 | recruiting | 44 | Beijing Sanbo Brain Hospital | Oct 2020 | |
| NCT04501705 | Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults | N/A | recruiting | 29 | Beijing Sanbo Brain Hospital | Aug 2020 | |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | P2 | unknown | 50 | Sun Yat-sen University | Aug 2020 | |
| NCT04714190 | A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression | P3 | unknown | 351 | RemeGen Co., Ltd. | Mar 2021 | |
| NCT04749394 | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | P2 | unknown | 42 | Chinese Academy of Medical Sciences | Mar 2021 | |
| NCT04591431 | ROME | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | P2 | unknown | 400 | Fondazione per la Medicina Personalizzata | Oct 2020 |
| NCT04296370 | A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation | P3 | unknown | 474 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2020 | |
| NCT05156970 | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | P2 | completed | 81 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Jun 2021 | |
| NCT07416409 | Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer | — | completed | 80 | Deraya University | Jun 2023 | |
| NCT05313282 | TRIPLET-III | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | P3 | unknown | 140 | Sun Yat-sen University | Jun 2022 |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | P1/P2 | recruiting | 29 | Fujian Cancer Hospital | Oct 2021 | |
| NCT04216550 | Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas | — | unknown | 600 | The First Affiliated Hospital of Zhengzhou University | Jan 2018 | |
| NCT05597527 | Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer | P2 | unknown | 35 | Fujian Cancer Hospital | Nov 2022 | |
| NCT04934618 | A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer | P2 | unknown | 85 | Nanfang Hospital, Southern Medical University | May 2020 | |
| NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | P2 | completed | 40 | UNC Lineberger Comprehensive Cancer Center | Jun 2012 | |
| NCT05380986 | Camrelizumab Combined With Apatinib Mesylate | N/A | unknown | 500 | Henan Cancer Hospital | May 2022 | |
| NCT05839197 | CCGLC-010 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC | P2 | unknown | 38 | Wan-Guang Zhang | May 2023 |
| NCT05189184 | HNSCC | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma | P2 | unknown | 30 | The First Affiliated Hospital of Zhengzhou University | Mar 2022 |
| NCT04195828 | Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer | P2 | completed | 106 | Fujian Medical University | Jun 2020 | |
| NCT04425135 | Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC | P2 | unknown | 59 | The First Affiliated Hospital of Xiamen University | Jul 2020 | |
| NCT03599778 | XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma | P1/P2 | unknown | 52 | Anhui Provincial Hospital | Sep 2018 | |
| NCT05942573 | Continuation of Serplulimab Plus Chemotherapy After First Progression in Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma: an Open-label, Randomised Phase II Trial | P2 | unknown | 107 | Tianjin Medical University Cancer Institute and Hospital | Dec 2022 | |
| NCT05760430 | The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma | P2 | unknown | 40 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Dec 2022 | |
| NCT05717738 | CCGLC-008 | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | recruiting | 300 | Tongji Hospital | Jan 2022 |
| NCT05142865 | Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas | P2 | unknown | 30 | Huazhong University of Science and Technology | Jan 2022 | |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | P2 | unknown | 172 | Sun Yat-sen University | Jul 2021 | |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | P2/P3 | unknown | 62 | Guangxi Medical University | Jun 2021 | |
| NCT04850040 | A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | P2 | unknown | 15 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | May 2021 | |
| NCT04609176 | SHR-1210 | Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | P2 | unknown | 64 | Peking University | Nov 2020 |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | P2/P3 | unknown | 301 | RemeGen Co., Ltd. | Apr 2018 | |
| NCT03192735 | Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer | P2 | unknown | 50 | Chang-Ming Huang, Prof. | Sep 2017 | |
| NCT04074564 | MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma | Early P1 | unknown | 60 | HRYZ Biotech Co. | Nov 2019 | |
| NCT03193814 | XHZL | Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer | P2 | withdrawn | 0 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Dec 2019 |
| NCT04517357 | A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | P2 | completed | 100 | Jiangsu HengRui Medicine Co., Ltd. | Oct 2020 | |
| NCT02101905 | Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | P1 | completed | 29 | National Cancer Institute (NCI) | Nov 2016 | |
| NCT03917966 | The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC | P2 | unknown | 80 | The First Affiliated Hospital of Zhengzhou University | Apr 2020 | |
| NCT04701060 | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | P2 | completed | 31 | Tianjin Medical University Cancer Institute and Hospital | Jan 2021 | |
| NCT00680901 | HER2 | LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib | P3 | completed | 545 | Novartis Pharmaceuticals | Jun 2008 |
| NCT04724226 | C-couple | Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma | P2 | unknown | 34 | Sun Yat-sen University | Sep 2021 |
| NCT05235100 | SPARE-02 | Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02） | P2 | completed | 30 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Sep 2021 |
| NCT00470704 | Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | P2 | completed | 87 | Nancy Lin, MD | May 2007 | |
| NCT01306045 | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | P2 | completed | 647 | National Cancer Institute (NCI) | Feb 2011 | |
| NCT04930315 | CAPT | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma | P2 | unknown | 78 | Zhejiang University | Sep 2021 |
| NCT04683198 | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC | P2 | unknown | 69 | Chinese Academy of Medical Sciences | Apr 2021 | |
| NCT04190745 | Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study | P2 | unknown | 116 | Zhejiang Cancer Hospital | Nov 2019 | |
| NCT03878472 | Neoadjuvant Immunotherapy for Resectable Gastric Cancer | P2 | completed | 25 | Qilu Hospital of Shandong University | Apr 2019 | |
| NCT04608409 | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | P1 | completed | 16 | Frederick R. Ueland, M.D. | Mar 2021 | |
| NCT04609293 | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma | — | unknown | 30 | Peking University First Hospital | Oct 2020 | |
| NCT05223088 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | P2 | completed | 40 | Fujian Cancer Hospital | Oct 2021 | |
| NCT04832204 | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases | P2 | unknown | 20 | Beijing Hospital | Mar 2021 | |
| NCT04950400 | A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC | N/A | unknown | 60 | Beijing Chest Hospital | Jul 2021 | |
| NCT04282278 | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor | P2 | unknown | 180 | Hebei Medical University Fourth Hospital | Jul 2020 | |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | P3 | unknown | 690 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2020 | |
| NCT03889626 | The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer | P3 | unknown | 242 | Fudan University | Mar 2019 | |
| NCT00770809 | Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery | P3 | completed | 305 | National Cancer Institute (NCI) | Feb 2009 | |
| NCT05550025 | TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer | P2 | unknown | 26 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Dec 2021 | |
| NCT03428425 | A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | P2 | unknown | 38 | Hebei Medical University | Feb 2018 | |
| NCT05001412 | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC | P1 | unknown | 36 | Zhou Chengzhi | Jan 2021 | |
| NCT06238752 | RENMIN-213 | First-line Apatinib Combined With Tislelizumab and Chemotherapy for Advanced GC | P2 | completed | 33 | Renmin Hospital of Wuhan University | Mar 2021 |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | P2 | unknown | 17 | Binkui Li | May 2023 | |
| NCT05171309 | Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | P2 | unknown | 35 | Nanfang Hospital, Southern Medical University | Jan 2021 | |
| NCT04612894 | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | P2 | unknown | 31 | Fudan University | Dec 2020 | |
| NCT04590625 | Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | P2 | unknown | 58 | Zhongshan Hospital Xiamen University | Oct 2020 | |
| NCT04440917 | IMplus | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma | P2 | unknown | 32 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Jun 2020 |
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | P2 | unknown | 116 | Fujian Cancer Hospital | Dec 2019 | |
| NCT04012827 | Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma | P2 | unknown | 108 | Sun Yat-sen University | Aug 2019 | |
| NCT03048877 | Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer | P3 | unknown | 118 | Peking Union Medical College Hospital | Dec 2016 | |
| NCT02824458 | A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations | P3 | unknown | 246 | Sun Yat-sen University | Jun 2016 | |
| NCT03742193 | PROACH | Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy | P2 | unknown | 43 | Ruijin Hospital | Aug 2019 |
| NCT04204577 | The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | P2 | unknown | 90 | Chinese PLA General Hospital | Nov 2019 | |
| NCT05277480 | OAIE | Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) | P2 | completed | 81 | Peking University People's Hospital | Mar 2022 |
| NCT04393506 | Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma | P1 | completed | 21 | Shanghai Jiao Tong University School of Medicine | Apr 2020 | |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | P2 | unknown | 68 | Sixth Affiliated Hospital, Sun Yat-sen University | May 2022 | |
| NCT04878107 | SABRE | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy | P2 | unknown | 88 | Wuhan University | Mar 2022 |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | P2 | unknown | 25 | Sun Yat-sen University | Sep 2020 | |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | P2 | unknown | 27 | Sun Yat-sen University | Sep 2020 | |
| NCT03531931 | Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial | — | unknown | 20 | The First Affiliated Hospital of Xiamen University | May 2018 | |
| NCT05095636 | Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | P2 | unknown | 102 | Fudan University | Mar 2021 | |
| NCT04625803 | Neoadjuvant Therapy for Locally Advanced Colon Cancer | P2 | completed | 64 | Zhejiang University | Jan 2021 | |
| NCT03491631 | Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors | P1 | unknown | 23 | Jiangsu HengRui Medicine Co., Ltd. | Nov 2018 | |
| NCT02875457 | Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin | P3 | unknown | 100 | Third Military Medical University | Sep 2016 | |
| NCT03801200 | Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC | P2 | unknown | 90 | Hubei Cancer Hospital | Sep 2020 | |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | P2 | unknown | 58 | Sun Yat-sen University | May 2020 | |
| NCT05290116 | HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma | P2 | unknown | 17 | Yunfei Yuan | Jul 2022 | |
| NCT04303741 | A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC | P2 | unknown | 46 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Mar 2020 | |
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | P2 | unknown | 40 | Hunan Cancer Hospital | Feb 2021 | |
| NCT04267549 | Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | P2 | unknown | 47 | Tianjin Medical University Cancer Institute and Hospital | May 2019 | |
| NCT04948125 | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma | P2 | unknown | 20 | Henan Cancer Hospital | Apr 2021 | |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | P1/P2 | unknown | 33 | Huiqiang Huang | Jul 2020 | |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | P2 | unknown | 63 | Hunan Cancer Hospital | Aug 2020 | |
| NCT04863430 | Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach | P2 | withdrawn | 0 | Peking University | May 2021 | |
| NCT05049681 | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | P3 | unknown | 234 | Feng Wang | Dec 2021 | |
| NCT05265793 | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma | P2 | unknown | 45 | Fudan University | Nov 2021 | |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | P2 | unknown | 60 | Peking Union Medical College Hospital | Jun 2020 | |
| NCT03777124 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | P2 | terminated | 25 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2019 | |
| NCT03932526 | Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer | P2 | unknown | 184 | Liaoning Cancer Hospital & Institute | Jun 2019 | |
| NCT03764293 | A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC | P3 | completed | 543 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2019 | |
| NCT03813784 | SHR-1210 | A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy | P3 | completed | 885 | Jiangsu HengRui Medicine Co., Ltd. | Mar 2019 |
| NCT04415385 | The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma | P2 | unknown | 48 | Zhejiang Cancer Hospital | Jun 2020 | |
| NCT04569916 | Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors | P2 | unknown | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Sep 2020 | |
| NCT04720131 | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. | P2 | completed | 28 | Beijing Friendship Hospital | Jan 2021 | |
| NCT04335006 | A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. | P3 | terminated | 80 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2020 | |
| NCT04901754 | CAMERA | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer | P2 | unknown | 38 | Henan Cancer Hospital | Jul 2021 |
| NCT03084939 | HER2 | Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer | P3 | completed | 351 | Hoffmann-La Roche | Apr 2017 |
| NCT05029453 | Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy | P4 | unknown | 60 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Aug 2021 | |
| NCT04782622 | The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy | — | unknown | 60 | The Affiliated Hospital of Qingdao University | Mar 2021 | |
| NCT03228043 | Apatinib for Resectable Colorectal Cancer | N/A | withdrawn | 0 | Nanchong Central Hospital | Mar 2020 | |
| NCT03857763 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy in Patients With Esophageal Squamous Cell Carcinoma | P2 | unknown | 40 | Hebei Medical University Fourth Hospital | Mar 2019 | |
| NCT04397770 | Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma | P2 | unknown | 40 | Peking University Cancer Hospital & Institute | May 2020 | |
| NCT04258644 | Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | P2 | unknown | 30 | Beijing Friendship Hospital | Mar 2020 | |
| NCT03741244 | TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT | P2 | unknown | 211 | The Second Hospital of Hebei Medical University | May 2019 | |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | P2 | unknown | 200 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Feb 2019 | |
| NCT01526369 | TH V THL | A Randomized Study of TH Versus THL in First Line Treatment of HER2-positive Metastatic Breast Cancer | P3 | completed | 75 | Cancer Trials Ireland | Feb 2012 |
| NCT04869488 | A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer | P2 | completed | 93 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2021 | |
| NCT04722718 | Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer | P2 | unknown | 34 | Jiuda Zhao | Feb 2021 | |
| NCT04792515 | CCWSA/OAFLAG | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer | P2 | unknown | 67 | First Affiliated Hospital Xi'an Jiaotong University | Jan 2021 |
| NCT04659785 | A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） | P1/P2 | unknown | 53 | Tianjin Medical University Second Hospital | Jul 2020 | |
| NCT04351308 | MAPAC | Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma | P2 | unknown | 60 | Peking University People's Hospital | May 2020 |
| NCT04201990 | CCA-MPLC | Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer | P1/P2 | unknown | 20 | ShiYue Li | Dec 2019 |
| NCT03271255 | ABST-C | Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) | P2 | unknown | 80 | Shenzhen People's Hospital | May 2018 |
| NCT03365765 | mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer | P3 | completed | 63 | Huashan Hospital | Feb 2018 | |
| NCT03580395 | Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer | P2/P3 | unknown | 200 | Hebei Medical University Fourth Hospital | Jun 2017 | |
| NCT02976896 | Poetry-1 | Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | P2 | completed | 43 | Yuhong Li | Aug 2016 |
| NCT04253873 | Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas | P2 | unknown | 40 | WuHui | Dec 2019 | |
| NCT03427242 | Apatinib for Advanced Biliary Carcinoma | P2 | unknown | 55 | Fudan University | Nov 2017 | |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | P1 | unknown | 10 | Liang Peng | Jan 2021 | |
| NCT04968002 | Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy | P2/P3 | unknown | 40 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Aug 2021 | |
| NCT05225844 | An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | P2 | unknown | 150 | Harbin Medical University | Jan 2019 | |
| NCT01711658 | TRYHARD | TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. | P2 | completed | 142 | Radiation Therapy Oncology Group | Mar 2013 |
| NCT04350190 | Apatinib Combined With PD-1 in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | P2 | completed | 25 | Wei Jiang | Jan 2021 | |
| NCT03816553 | SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer | P2 | completed | 45 | Sun Yat-sen University | Jan 2019 | |
| NCT03389256 | Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC | P2 | unknown | 144 | Sichuan Cancer Hospital and Research Institute | Dec 2018 | |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | P2 | unknown | 27 | Beijing Tsinghua Chang Gung Hospital | Aug 2020 | |
| NCT04006821 | PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma | P2 | unknown | 30 | China Medical University, China | Jul 2019 | |
| NCT04000295 | Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer | P3 | unknown | 280 | Jiangsu HengRui Medicine Co., Ltd. | Aug 2019 | |
| NCT00667251 | Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer | P3 | completed | 652 | Novartis Pharmaceuticals | Oct 2008 | |
| NCT04446091 | MAC | A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) | P1/P2 | unknown | 40 | Zhejiang Cancer Hospital | Jul 2020 |
| NCT04670913 | Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy | P2 | unknown | 30 | Junling Li | Jun 2021 | |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | P2 | unknown | 28 | Peking Union Medical College Hospital | Oct 2019 | |
| NCT04348032 | APPROVE | Apatinib Combined With PLD vs PLD for Platinum-resistant Recurrent Ovarian Cancer | P2 | unknown | 152 | Chinese Academy of Medical Sciences | Mar 2018 |
| NCT04345783 | Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer | P2 | unknown | 30 | Beijing Friendship Hospital | Jan 2018 | |
| NCT00251433 | GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer | P1 | terminated | 53 | Novartis Pharmaceuticals | Sep 2005 | |
| NCT01160211 | A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | P3 | completed | 369 | Novartis Pharmaceuticals | May 2011 | |
| NCT04411706 | A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma | P2 | unknown | 46 | Xin-Hua Xu | Jun 2020 | |
| NCT04572542 | Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer | P1/P2 | unknown | 46 | The First Affiliated Hospital of Xiamen University | Jan 2020 | |
| NCT04203485 | PD-L1 | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | P3 | unknown | 762 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2020 |
| NCT03986515 | Apatinib Plus SHR1210 in Advanced Mucosal Melanoma | P2 | unknown | 40 | Henan Cancer Hospital | Jun 2019 | |
| NCT01622868 | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer | P2 | completed | 143 | National Cancer Institute (NCI) | Dec 2012 | |
| NCT04182724 | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | P1/P2 | unknown | 57 | Chinese PLA General Hospital | Nov 2019 | |
| NCT05025033 | Chemotherapy Combined With Apatinib and PD-1 Antibody | P2 | completed | 30 | Tianjin Medical University Cancer Institute and Hospital | May 2019 | |
| NCT03083041 | NSCLC | A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) | P2 | completed | 210 | Jiangsu HengRui Medicine Co., Ltd. | Mar 2017 |
| NCT04239443 | Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer | P2 | unknown | 120 | Hunan Cancer Hospital | Jan 2019 | |
| NCT03396211 | A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer | P1 | completed | 30 | Elevar Therapeutics | Dec 2017 | |
| NCT04188847 | First-line Chemotherapy for Recurrent Cervical Cancer | P2 | completed | 37 | Lei Li | Dec 2019 | |
| NCT03792503 | Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen | P4 | withdrawn | 0 | Xinqiao Hospital of Chongqing | Feb 2019 | |
| NCT04490421 | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | P3 | unknown | 45 | Fuzhou General Hospital | Aug 2020 | |
| NCT01619111 | DETECT III | DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs | P3 | completed | 105 | Prof. Wolfgang Janni | Feb 2012 |
| NCT04447274 | A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS | P2 | unknown | 20 | Chinese Academy of Medical Sciences | Jul 2020 | |
| NCT04128800 | Appatinib Combined With S-1 in the Treatment of Small Cell Lung Cancer | P2 | unknown | 20 | Tianjin Medical University Cancer Institute and Hospital | Oct 2019 | |
| NCT04101929 | Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen | P2 | unknown | 126 | Fudan University | Oct 2019 | |
| NCT04035876 | SHR-1210 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | P1/P2 | unknown | 120 | Zhejiang University | Jul 2019 |
| NCT03787251 | A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib | P2 | withdrawn | 0 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Jan 2019 | |
| NCT03243838 | LANCET | Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer | P2 | completed | 31 | Guangdong Provincial People's Hospital | Aug 2018 |
| NCT04185649 | The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer | P3 | unknown | 410 | Bio-Thera Solutions | Jul 2018 | |
| NCT03475589 | Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations | P4 | unknown | 217 | Sun Yat-sen University | Feb 2018 | |
| NCT02989259 | Apatinib for Advanced Non-squamous Head and Neck Cancer | P2 | unknown | 30 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Dec 2016 | |
| NCT03267654 | Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | P2 | unknown | 100 | Qilu Pharmaceutical Co., Ltd. | Oct 2017 | |
| NCT03609489 | A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma | P2 | unknown | 40 | First Affiliated Hospital of Guangxi Medical University | Sep 2018 | |
| NCT03925233 | Breast Cancer Treatment Based on Organ-like Culture | — | unknown | 300 | Xijing Hospital | Jan 2019 | |
| NCT03075462 | A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | P1 | completed | 98 | Jiangsu HengRui Medicine Co., Ltd. | Mar 2017 | |
| NCT04089657 | ASGARD | Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens | P2 | unknown | 40 | Fujian Cancer Hospital | Dec 2019 |
| NCT04297202 | HCC-009 | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular Carcinoma | P2 | unknown | 20 | The First Affiliated Hospital with Nanjing Medical University | Dec 2019 |
| NCT03411967 | Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC | P2 | unknown | 20 | Zigong No.1 Peoples Hospital | Feb 2018 | |
| NCT03229096 | Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer | P2 | unknown | 35 | Shanghai Zhongshan Hospital | Feb 2017 | |
| NCT00281658 | Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2 | P3 | completed | 444 | Novartis Pharmaceuticals | Jan 2006 | |
| NCT03758677 | Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation | P2 | unknown | 30 | The First Hospital of Jilin University | Aug 2020 | |
| NCT04202978 | Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer | P1/P2 | unknown | 23 | Zhongshan Hospital Xiamen University | Mar 2020 | |
| NCT03389087 | Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer | P2 | unknown | 60 | Henan Cancer Hospital | Nov 2017 | |
| NCT04067986 | Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer | P1/P2 | unknown | 62 | Zhongshan Hospital Xiamen University | Aug 2019 | |
| NCT02943252 | The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer | P2 | unknown | 30 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Oct 2016 | |
| NCT03775928 | Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer | P2 | unknown | 80 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Dec 2018 | |
| NCT03654612 | Y-HR2017-025 | Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies | P1/P2 | unknown | 30 | China International Medical Foundation | Oct 2018 |
| NCT03671265 | Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC | N/A | unknown | 20 | Tianjin Medical University Cancer Institute and Hospital | Sep 2018 | |
| NCT04428086 | A Pharmacokinetic Interaction Study Between Apatinib and Rosuvastatin or Metformin in Solid Tumor Subjects. | P1 | completed | 19 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2020 | |
| NCT03417895 | PASSION | SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy | P2 | completed | 59 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2018 |
| NCT03254654 | Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer | P2 | completed | 66 | Fudan University | Aug 2017 | |
| NCT03612219 | Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma | P2 | unknown | 240 | Wei Jiang | Jul 2018 | |
| NCT02158507 | ABT-888 | Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer | N/A | completed | 20 | University of Alabama at Birmingham | Sep 2014 |
| NCT00490139 | ALTTO | ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D | P3 | completed | 8,381 | Novartis Pharmaceuticals | May 2007 |
| NCT04383977 | Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer | P2 | unknown | 54 | Jiangsu HengRui Medicine Co., Ltd. | May 2020 | |
| NCT04286711 | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | P1/P2 | unknown | 52 | China Medical University, China | Mar 2020 | |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | P1/P2 | unknown | 20 | Sichuan Cancer Hospital and Research Institute | Nov 2019 | |
| NCT03711279 | A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma | P2 | terminated | 99 | Jiangsu HengRui Medicine Co., Ltd. | Nov 2018 | |
| NCT04457180 | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects | P1 | completed | 18 | Jiangsu HengRui Medicine Co., Ltd. | Nov 2020 | |
| NCT04690231 | Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma | N/A | completed | 79 | Peking University People's Hospital | Dec 2020 | |
| NCT03954756 | Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer | P2 | unknown | 35 | Henan Cancer Hospital | Jun 2019 | |
| NCT03913182 | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer | P2 | unknown | 39 | Shanghai Chest Hospital | Apr 2019 | |
| NCT04047017 | GTN | Camrelizumab Combined With Apatinib for Recurrent Resistant GTN | P2 | completed | 20 | Peking Union Medical College Hospital | Aug 2019 |
| NCT04322552 | A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects | P1 | completed | 18 | Jiangsu HengRui Medicine Co., Ltd. | Mar 2020 | |
| NCT04174339 | SHR-1210 | PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | N/A | unknown | 20 | Fujian Cancer Hospital | Dec 2019 |
| NCT04414852 | A Study to Evaluate the Pharmacokinetics of Apatinib in Subjects With Impaired Renal Function | P1 | unknown | 24 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2020 | |
| NCT03709953 | Spark-AL003 | Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma | P2 | unknown | 33 | Guangzhou Institute of Respiratory Disease | Oct 2018 |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma | P2 | terminated | 11 | Peking University | Sep 2017 | |
| NCT03955354 | PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma | P2 | unknown | 30 | Peking University Cancer Hospital & Institute | Mar 2019 | |
| NCT04390984 | Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients | P1 | unknown | 22 | Jiangsu HengRui Medicine Co., Ltd. | May 2020 | |
| NCT03397199 | Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer | P2 | unknown | 120 | Henan Cancer Hospital | Jan 2018 | |
| NCT03080805 | PHOEBE | Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE) | P3 | unknown | 240 | Jiangsu HengRui Medicine Co., Ltd. | May 2017 |
| NCT03092895 | A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | P2 | completed | 157 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2017 | |
| NCT03603756 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | P2 | unknown | 45 | Chinese Academy of Medical Sciences | Jul 2018 | |
| NCT03463876 | RESCUE | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) | P2 | completed | 190 | Jiangsu HengRui Medicine Co., Ltd. | Mar 2018 |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | P2 | terminated | 10 | University of Southern California | Jul 2013 | |
| NCT03085368 | A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin | P2/P3 | unknown | 482 | Peking Union Medical College Hospital | Mar 2017 | |
| NCT03412994 | Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer | P2 | unknown | 60 | Liqiang Zhong | Feb 2018 | |
| NCT03262545 | Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer | P2 | unknown | 60 | Sichuan Cancer Hospital and Research Institute | Aug 2017 | |
| NCT02731352 | Study of Apatinib in Patients With Differentiated Thyroid Cancer | P2 | completed | 20 | Peking Union Medical College Hospital | Mar 2016 | |
| NCT03945604 | A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC | P1 | completed | 32 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2019 | |
| NCT04682249 | Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC | P2 | withdrawn | 0 | Sun Yat-sen University | Dec 2020 | |
| NCT03986385 | Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction | P3 | unknown | 180 | Hebei Medical University | Jun 2019 | |
| NCT03793725 | HZ-T-PD1-APA | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC | P2 | unknown | 30 | Yanqiao Zhang | Jan 2019 |
| NCT02650752 | CNS | Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases | P1 | completed | 11 | Memorial Sloan Kettering Cancer Center | Jan 2016 |
| NCT04642664 | ACABC | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | P2 | completed | 22 | Peking Union Medical College Hospital | Dec 2018 |
| NCT04165174 | PD-1 Monoclonal Antibody Plus Apatinib Combined With SBRT in HCC With PVTT | P2 | unknown | 20 | Huazhong University of Science and Technology | Dec 2019 | |
| NCT04126993 | Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma | P2 | unknown | 80 | Tianjin Medical University Cancer Institute and Hospital | Jun 2019 | |
| NCT04126811 | Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma | P2 | unknown | 120 | Tianjin Medical University Cancer Institute and Hospital | Jun 2019 | |
| NCT03788174 | Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma | P2 | unknown | 26 | Fujian Cancer Hospital | Feb 2019 | |
| NCT03811054 | NSCLC | The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) | P2 | unknown | 60 | Beijing Chest Hospital | Dec 2018 |
| NCT03428022 | AFLC | Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC | P3 | unknown | 54 | Shenzhen People's Hospital | Dec 2017 |
| NCT03167385 | Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma | P2 | unknown | 20 | Tianjin Medical University Cancer Institute and Hospital | Mar 2017 | |
| NCT03029013 | Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer | N/A | unknown | 30 | Third Military Medical University | Jan 2017 | |
| NCT02836847 | Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | P2 | unknown | 152 | Shanghai Jiao Tong University School of Medicine | Jul 2016 | |
| NCT02733107 | The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer | P2 | unknown | 25 | Third Military Medical University | Mar 2016 | |
| NCT03942068 | Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer | P2 | unknown | 35 | Henan Cancer Hospital | Sep 2019 | |
| NCT03707639 | Study of the Combination of Apatinib and POF | P2 | unknown | 26 | Fujian Cancer Hospital | Nov 2018 | |
| NCT03349866 | A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction | P2 | unknown | 48 | Hebei Medical University | Nov 2017 | |
| NCT03472365 | A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer | P2 | completed | 67 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2018 | |
| NCT03267121 | A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck | P2 | completed | 38 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Oct 2017 | |
| NCT03718624 | A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | P2 | unknown | 36 | Hebei Medical University | Oct 2018 | |
| NCT03598348 | Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer | P3 | unknown | 288 | Huazhong University of Science and Technology | Jan 2018 | |
| NCT04014101 | SHR-1210 | SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma | P2 | unknown | 40 | Shanghai Zhongshan Hospital | Jun 2019 |
| NCT03567135 | Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma | — | unknown | 60 | Fuzhou General Hospital | Oct 2017 | |
| NCT03394287 | A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC | P2 | completed | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jan 2018 | |
| NCT03116555 | Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA | P2 | unknown | 37 | China Medical University, China | Apr 2017 | |
| NCT02426034 | A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer | P4 | completed | 2,004 | Jiangsu HengRui Medicine Co., Ltd. | May 2015 | |
| NCT02878057 | CABC006 | Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006) | P2 | completed | 30 | Peking University Cancer Hospital & Institute | May 2016 |
| NCT03547804 | MK 01 | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer | P2 | completed | 31 | The First Hospital of Jilin University | May 2018 |
| NCT03377842 | Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer | P2 | unknown | 100 | Sichuan Provincial People's Hospital | Jan 2018 | |
| NCT02874651 | ADVANCE | ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy | P2 | terminated | 25 | Sun Yat-sen University | Oct 2016 |
| NCT03634059 | A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations | N/A | unknown | 80 | Hebei Medical University Fourth Hospital | Aug 2018 | |
| NCT03702491 | Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma | P2 | unknown | 138 | Eastern Hepatobiliary Surgery Hospital | Aug 2018 | |
| NCT03651219 | Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer | P3 | unknown | 90 | Beijing Chest Hospital | Sep 2018 | |
| NCT03662035 | ASPC | Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer | P2 | unknown | 30 | Changzhou No.2 People's Hospital | Sep 2018 |
| NCT03390062 | A Study of Apatinib in Recurrent or Recurrent High-grade Glioma | P2 | unknown | 30 | West China Hospital | Jan 2018 | |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | P1/P2 | unknown | 48 | West China Hospital | Jun 2017 | |
| NCT03213587 | NPC | Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) | P2 | unknown | 51 | Zhejiang Cancer Hospital | Jul 2017 |
| NCT03190239 | XQonc-007 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients | P2 | withdrawn | 0 | Xinqiao Hospital of Chongqing | Jul 2017 |
| NCT04341090 | A Food Effect Study of Apatinib Mesylate in Healthy Subjects | P1 | completed | 42 | Jiangsu HengRui Medicine Co., Ltd. | May 2020 | |
| NCT03407976 | APPEASE | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | P1 | terminated | 5 | University of Utah | Jun 2018 |
| NCT03950141 | Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer | P2 | unknown | 30 | Beijing Hospital | Jul 2017 | |
| NCT00508274 | Lapatinib +Capecitabine Treatment for Advanced Metastatic Breast Cancer in Women From China | P3 | terminated | 52 | Novartis Pharmaceuticals | Jul 2007 | |
| NCT00444535 | Lapatinib and Bevacizumab for Metastatic Breast Cancer | P2 | completed | 52 | Novartis Pharmaceuticals | Feb 2007 | |
| NCT03587129 | Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | P2 | terminated | 1 | First Affiliated Hospital of Harbin Medical University | Jul 2018 | |
| NCT02213042 | Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer | P2 | terminated | 42 | Novartis Pharmaceuticals | Oct 2014 | |
| NCT03104283 | Apatinib for the Elderly Advanced Gastric Cancer | P2 | completed | 48 | Affiliated Hospital of Qinghai University | Jun 2017 | |
| NCT03645200 | Treatment of Carrying TP53 Harmful Mutations | P1 | unknown | 60 | Tianjin Medical University Second Hospital | Jul 2019 | |
| NCT03735082 | Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer | P2 | unknown | 29 | Chinese Academy of Medical Sciences | Nov 2018 | |
| NCT03547375 | Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy | P2 | unknown | 69 | Anhui Provincial Hospital | Jun 2018 | |
| NCT03546855 | Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy. | P2 | unknown | 69 | Anhui Provincial Hospital | Jun 2018 | |
| NCT02362958 | A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer | P2 | completed | 159 | Sun Yat-sen University | Jan 2015 | |
| NCT04180007 | APT-01 | Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers | P2 | unknown | 10 | Nanjing First Hospital, Nanjing Medical University | Apr 2019 |
| NCT03300765 | Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer | P2 | unknown | 20 | Xiayun He, MD | Jul 2017 | |
| NCT00543504 | Bevacizumab in Multiple Phase I Combinations | P1 | completed | 343 | M.D. Anderson Cancer Center | Oct 2007 | |
| NCT03261791 | Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection | P2 | unknown | 30 | Shanghai Zhongshan Hospital | Jul 2017 | |
| NCT04260113 | AIAC | Apatinib for Inoperable Advanced Chondrosarcoma | N/A | completed | 40 | Peking University People's Hospital | Oct 2019 |
| NCT03868852 | Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children | P1/P2 | unknown | 48 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Jan 2019 | |
| NCT03180476 | Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma | P2 | completed | 21 | Sichuan Cancer Hospital and Research Institute | Apr 2017 | |
| NCT04152681 | Effect and Safety of Apatinib on Radiation-Induced Brain Injury | P2 | unknown | 36 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Oct 2019 | |
| NCT02980809 | Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer | P2 | unknown | 60 | First Hospitals affiliated to the China PLA General Hospital | Mar 2017 | |
| NCT03349827 | HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer | N/A | terminated | 20 | Wuhan University | Jan 2018 | |
| NCT03457467 | Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer | P2 | unknown | 30 | Yan Li | Mar 2018 | |
| NCT03722875 | SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery | N/A | unknown | 45 | Shanghai Zhongshan Hospital | Dec 2018 | |
| NCT03539172 | RASS | Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study | P2 | unknown | 61 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Jun 2018 |
| NCT03129698 | The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer | P2 | unknown | 52 | Junling Li | Apr 2017 | |
| NCT03104335 | Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial | P2 | withdrawn | 0 | Peking University People's Hospital | Apr 2017 | |
| NCT03219593 | Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer | P2 | unknown | 30 | The First Affiliated Hospital of Bengbu Medical University | Sep 2017 | |
| NCT03144843 | Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer. | P2 | unknown | 110 | Sun Yat-sen University | Jan 2017 | |
| NCT04338438 | Efficacy and Safety of Apatinib Combined With S-1 for Patients With Advance Gastric Cancer | P2 | completed | 37 | Beijing Friendship Hospital | May 2015 | |
| NCT03359018 | APFAO | Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma | P2 | completed | 43 | Peking University People's Hospital | Jan 2018 |
| NCT03416231 | NSCLC | Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC) | P2 | unknown | 20 | Affiliated Hospital of North Sichuan Medical College | Nov 2016 |
| NCT03650738 | This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment | P2 | unknown | 60 | The First Affiliated Hospital with Nanjing Medical University | Sep 2018 | |
| NCT03631862 | Treatment of Newly Diagnosed Peripheral T-cell Lymphoma | P4 | unknown | 100 | Zhengzhou University | Sep 2018 | |
| NCT03510416 | Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma | P2 | unknown | 22 | Shanghai Zhongshan Hospital | May 2018 | |
| NCT03403452 | Apatinib in the Treatment of Metastatic Colorectal Cancer | P2 | unknown | 33 | Fudan University | Jan 2018 | |
| NCT03243643 | HS:Hansoh; | Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors | P1 | unknown | 80 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Aug 2017 |
| NCT03127319 | A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases | P2 | unknown | 40 | Affiliated Hospital of Hebei University | Jul 2017 | |
| NCT03285906 | An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric | P2/P3 | unknown | 30 | Tianjin Medical University Cancer Institute and Hospital | Mar 2017 | |
| NCT03020979 | A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites | P2 | unknown | 120 | The First Affiliated Hospital of Bengbu Medical University | Jan 2017 | |
| NCT03652857 | Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer | P2 | completed | 30 | Yongchang Zhang | Jan 2017 | |
| NCT02942693 | Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma | P2 | unknown | 50 | Shanghai Proton and Heavy Ion Center | Nov 2016 | |
| NCT03273595 | Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer | P2 | unknown | 100 | Xijing Hospital | Jul 2016 | |
| NCT02704767 | Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma | P2 | unknown | 60 | First Affiliated Hospital of Kunming Medical University | Jun 2016 | |
| NCT03190616 | Apatinib in Refractory Colorectal Cancer | P2 | completed | 54 | The First Affiliated Hospital with Nanjing Medical University | Jul 2017 | |
| NCT03193424 | Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | P2 | unknown | 120 | The First Affiliated Hospital of Zhengzhou University | Oct 2016 | |
| NCT00553358 | Neo ALTTO | Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | P3 | completed | 455 | Novartis Pharmaceuticals | Jan 2008 |
| NCT01808573 | NALA | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting | P3 | completed | 621 | Puma Biotechnology, Inc. | Mar 2013 |
| NCT03130270 | Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma | P2 | unknown | 29 | Guilin Medical University, China | Jan 2017 | |
| NCT03334591 | Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer | P2 | unknown | 60 | Anhui Provincial Hospital | Oct 2017 | |
| NCT03393507 | A Study of Apatinib Treatment in for Advanced Ovarian Cancer | P2 | unknown | 34 | The People's Hospital of Leshan | Aug 2017 | |
| NCT01636908 | ICK | Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | N/A | completed | 43 | Amsterdam UMC, location VUmc | Aug 2011 |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | P2 | unknown | 30 | The First Affiliated Hospital of Zhengzhou University | Feb 2018 | |
| NCT03383237 | Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma | P2 | unknown | 20 | Henan Cancer Hospital | Nov 2017 | |
| NCT03356600 | Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer | P2 | unknown | 44 | Shanxi Province Cancer Hospital | Dec 2017 | |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | P1 | unknown | 30 | Peking University Third Hospital | May 2016 | |
| NCT00272987 | ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib | P3 | terminated | 63 | Novartis Pharmaceuticals | Dec 2005 | |
| NCT00684983 | Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | P2 | completed | 64 | National Cancer Institute (NCI) | Jul 2008 | |
| NCT03376191 | Apatinib in Advanced Non-squamous，NSCLC | — | unknown | 100 | Jian Fang | May 2017 | |
| NCT03170310 | Apatinib Treatment for Advanced Esophagus Cancer | P2 | unknown | 60 | Henan Cancer Hospital | Feb 2017 | |
| NCT00367471 | Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer. | P1 | completed | 31 | Novartis Pharmaceuticals | Dec 2006 | |
| NCT02867956 | Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer | P2 | completed | 35 | Sun Yat-sen University | Aug 2016 | |
| NCT02529878 | Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer | P2 | unknown | 30 | The First Affiliated Hospital of Zhejiang Chinese Medical University | Aug 2015 | |
| NCT03256721 | Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC | P2 | terminated | 37 | Fuzhou General Hospital | Aug 2017 | |
| NCT00820872 | Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer | P2 | completed | 30 | Alliance for Clinical Trials in Oncology | Feb 2009 | |
| NCT02329860 | AHELP | Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) | P3 | completed | 400 | Jiangsu HengRui Medicine Co., Ltd. | Mar 2014 |
| NCT02230553 | M14LTK | Lapatinib Plus Trametinib in KRAS Mutant NSCLC | P1/P2 | completed | 35 | The Netherlands Cancer Institute | Oct 2014 |
| NCT03100955 | A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer | P3 | unknown | 120 | Qingdao University | Mar 2017 | |
| NCT03424291 | A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma | P2 | unknown | 60 | Henan Cancer Hospital | Jul 2017 | |
| NCT00436566 | Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery | P2 | completed | 122 | Mayo Clinic | Mar 2007 | |
| NCT03344614 | A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer | P2 | unknown | 30 | Chinese PLA General Hospital | Jul 2017 | |
| NCT03725423 | Apatinib for Advanced Lung Squmamous Carcinoma | P4 | unknown | 50 | Xuzhou Central Hospital | Oct 2018 | |
| NCT03520257 | The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus | P2 | unknown | 50 | Guangxi Medical University | May 2018 | |
| NCT03511703 | The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients | P2 | unknown | 40 | Guangxi Medical University | May 2018 | |
| NCT03244774 | Phase I Study of the Combination of Apatinib and POF | P1 | unknown | 18 | Fujian Cancer Hospital | Jan 2018 | |
| NCT03376737 | Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma | P2 | unknown | 120 | Henan Cancer Hospital | Oct 2017 | |
| NCT03225937 | HERACLES | Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer | P2 | unknown | 54 | Fondazione del Piemonte per l'Oncologia | Aug 2012 |
| NCT03274011 | Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | P2 | completed | 40 | Fudan University | Jul 2017 | |
| NCT03224221 | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | P2 | unknown | 189 | The First Affiliated Hospital of Anhui Medical University | Mar 2017 | |
| NCT03542422 | Apatinib as First -Line Treatment for Advanced Esophagus Cancer | P2 | unknown | 50 | Affiliated Hospital of North Sichuan Medical College | Jun 2018 | |
| NCT03086785 | Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer | P2 | unknown | 120 | Hebei Medical University Fourth Hospital | Nov 2016 | |
| NCT02945852 | Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy. | P2 | completed | 40 | Fan Yun, MD | Oct 2016 | |
| NCT03114085 | Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma | P2 | unknown | 170 | First Affiliated Hospital of Guangxi Medical University | May 2017 | |
| NCT01783756 | Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis | P1/P2 | completed | 9 | Jonsson Comprehensive Cancer Center | Jun 2013 | |
| NCT03251443 | A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | P2 | completed | 34 | Peking Union Medical College Hospital | Aug 2017 | |
| NCT03121846 | Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy | P2 | unknown | 80 | Tianjin Medical University Cancer Institute and Hospital | May 2017 | |
| NCT03535961 | Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer | P2 | completed | 32 | Chinese Academy of Medical Sciences | May 2017 | |
| NCT03096184 | A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers | P2 | unknown | 38 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Dec 2016 | |
| NCT03298074 | Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | P2 | unknown | 60 | Yang Zhijun | Oct 2017 | |
| NCT03376958 | Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma | P4 | completed | 32 | Zhengzhou University | Jan 2017 | |
| NCT03210064 | Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients | P2 | unknown | 42 | Hui ting Xu，MD | May 2017 | |
| NCT02764268 | Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer | N/A | completed | 60 | Jiangsu HengRui Medicine Co., Ltd. | Nov 2016 | |
| NCT03163381 | Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study. | P2 | unknown | 40 | Henan Cancer Hospital | Apr 2017 | |
| NCT03398122 | HCC | Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma | N/A | unknown | 248 | Tianjin Medical University Cancer Institute and Hospital | Nov 2017 |
| NCT02702323 | Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study | P2/P3 | unknown | 40 | Zhejiang Cancer Hospital | Mar 2016 | |
| NCT02711969 | YN968D1 | A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment | P1 | completed | 6 | Bukwang Pharmaceutical | Mar 2016 |
| NCT02727309 | A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients | P1/P2 | unknown | 30 | Peking University Cancer Hospital & Institute | Oct 2015 | |
| NCT03255811 | Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer | N/A | unknown | 40 | DongMa | Mar 2017 | |
| NCT03144856 | Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers | P2 | unknown | 39 | Sun Yat-sen University | Feb 2017 | |
| NCT03422445 | A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma | P2 | unknown | 30 | Peking University Cancer Hospital & Institute | Jan 2018 | |
| NCT02596256 | AHEAD-301 | Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301) | P2 | unknown | 80 | Chinese PLA General Hospital | Apr 2016 |
| NCT03271073 | A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer | P2 | unknown | 20 | Beijing Friendship Hospital | Feb 2016 | |
| NCT02073487 | TEAL | Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel | P2 | completed | 32 | The Methodist Hospital Research Institute | Feb 2014 |
| NCT01827163 | Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer | P2 | completed | 20 | Memorial Sloan Kettering Cancer Center | Apr 2013 | |
| NCT01700010 | Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer | P2 | withdrawn | 0 | University of Michigan Rogel Cancer Center | Nov 2012 | |
| NCT03320629 | A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma | P2 | terminated | 7 | Hebei Medical University Fourth Hospital | Nov 2017 | |
| NCT03135977 | Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy | P2 | unknown | 36 | Sichuan Cancer Hospital and Research Institute | Mar 2017 | |
| NCT03046979 | HCC | Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC) | P2 | unknown | 30 | Tianjin Medical University Cancer Institute and Hospital | Dec 2016 |
| NCT02775370 | A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck | P2 | unknown | 68 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | May 2016 | |
| NCT02645864 | Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma | P1 | completed | 12 | Peking University | Jan 2016 | |
| NCT02422199 | A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab | P1/P2 | unknown | 128 | Jiangsu HengRui Medicine Co., Ltd. | May 2015 | |
| NCT02073916 | STELA | T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer | P1 | completed | 24 | Jenny C. Chang, MD | Oct 2013 |
| NCT01300962 | Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer | P1 | completed | 47 | UNC Lineberger Comprehensive Cancer Center | Aug 2011 | |
| NCT00939523 | Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | P2 | completed | 9 | Cedars-Sinai Medical Center | Jul 2009 | |
| NCT03030937 | Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA | P2 | unknown | 74 | Fujian Cancer Hospital | Feb 2017 | |
| NCT03129256 | EASE | An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer | P2 | completed | 52 | Changzhou Cancer Hospital of Soochow University | Dec 2016 |
| NCT03348098 | Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer | P2 | unknown | 20 | Tianjin Medical University Cancer Institute and Hospital | Sep 2017 | |
| NCT03007446 | The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer | P2 | unknown | 20 | Chinese PLA General Hospital | Nov 2016 | |
| NCT02974933 | Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | P2 | unknown | 48 | Wuling Ou | Nov 2016 | |
| NCT02942329 | Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer | P1/P2 | unknown | 60 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Oct 2016 | |
| NCT02697838 | Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer | P2 | unknown | 20 | Fujian Cancer Hospital | Aug 2016 | |
| NCT03245307 | A Study To Test The Effect Of Apatinib On P450 Enzymes | P1 | unknown | 20 | Jiangsu HengRui Medicine Co., Ltd. | Aug 2017 | |
| NCT02995187 | SCLC | Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC) | P2 | unknown | 25 | Chinese Academy of Medical Sciences | Dec 2016 |
| NCT02829385 | Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients | P2 | unknown | 53 | Shoucheng Ma | Jun 2016 | |
| NCT03064243 | A Phase II Study of Apatinib in STS Patients | P2 | unknown | 53 | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Mar 2017 | |
| NCT02852798 | Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC | — | unknown | 60 | Jiangsu ShengDiYa Medicine Co., Ltd. | Aug 2016 | |
| NCT00759642 | Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy | P2 | terminated | 33 | University of Kansas Medical Center | Mar 2009 | |
| NCT02844881 | Study of Apatinib and MASCT in Patients With Advanced Solid Tumors | P1/P2 | unknown | 60 | The First People's Hospital of Lianyungang | Jul 2016 | |
| NCT02848794 | Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma | P1/P2 | unknown | 40 | The First People's Hospital of Lianyungang | Jul 2016 | |
| NCT02510469 | Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells | P2/P3 | unknown | 48 | Hebei Medical University | Jul 2015 | |
| NCT00826241 | Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma | P2 | completed | 58 | National Institutes of Health Clinical Center (CC) | Jan 2009 | |
| NCT03199677 | A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer | P2 | unknown | 40 | Chinese Academy of Medical Sciences | Jul 2017 | |
| NCT03026881 | A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | P1 | unknown | 24 | Jiangsu HengRui Medicine Co., Ltd. | Jan 2017 | |
| NCT03071042 | A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma | P1 | unknown | 12 | Sir Run Run Shaw Hospital | Oct 2015 | |
| NCT00777101 | Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | P2 | completed | 233 | Puma Biotechnology, Inc. | Feb 2009 | |
| NCT01485926 | TCHL Phase II | A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. | P2 | completed | 120 | Cancer Trials Ireland | Oct 2010 |
| NCT03132025 | Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer | P2 | unknown | 40 | Yanqiao Zhang | Apr 2017 | |
| NCT01137994 | A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer | P2 | withdrawn | 0 | GlaxoSmithKline | Oct 2011 | |
| NCT00968968 | Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | P3 | terminated | 37 | Novartis Pharmaceuticals | Jan 2010 | |
| NCT00820222 | HER2 | Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | P3 | completed | 540 | Novartis Pharmaceuticals | Apr 2009 |
| NCT00073528 | GW572016 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | P3 | completed | 1,286 | Novartis Pharmaceuticals | Dec 2003 |
| NCT00263588 | Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | P2 | completed | 242 | Novartis Pharmaceuticals | Dec 2005 | |
| NCT03276156 | Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer | P1 | unknown | 12 | Zhejiang Cancer Hospital | Feb 2016 | |
| NCT03384511 | The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. | P4 | completed | 38 | Shandong Cancer Hospital and Institute | Sep 2016 | |
| NCT02711007 | Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy | P2/P3 | completed | 37 | GUO WEI | Mar 2016 | |
| NCT03660761 | Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors | P2 | completed | 25 | Rongjie Tao | Mar 2016 | |
| NCT00709761 | Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC | P2 | completed | 60 | Novartis Pharmaceuticals | Jul 2008 | |
| NCT02863367 | OECTAPGAMPC | A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer | P2 | unknown | 30 | Tianjin Medical University Cancer Institute and Hospital | Aug 2016 |
| NCT02780778 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | P2/P3 | unknown | 20 | Tianjin Medical University Cancer Institute and Hospital | May 2016 | |
| NCT02726854 | Apslpanc | Apatinib as Second-line Treatment of Advanced Pancreatic Cancer | P2 | unknown | 30 | First Affiliated Hospital Xi'an Jiaotong University | Apr 2016 |
| NCT02544737 | Apatinib for Metastatic Esophageal Cancer. | P2 | unknown | 29 | Hangzhou Cancer Hospital | Sep 2015 | |
| NCT02509806 | Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer | P2/P3 | unknown | 48 | Hebei Medical University | Jul 2015 | |
| NCT02540824 | Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer | P2 | unknown | 40 | Tongji University | Jan 2015 | |
| NCT01973660 | PAMELA | PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | P2 | completed | 151 | SOLTI Breast Cancer Research Group | Oct 2013 |
| NCT01730677 | LV | Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab | P2 | unknown | 150 | National Cancer Center, Korea | Jul 2012 |
| NCT01190241 | TSAP | Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study | N/A | terminated | 45 | Amsterdam UMC, location VUmc | Aug 2010 |
| NCT00450203 | ST03 | Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | P2/P3 | unknown | 1,103 | Professor David Cunningham | Oct 2007 |
| NCT01382706 | Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder | P2 | terminated | 15 | University of Southern California | Jun 2011 | |
| NCT02998242 | ARCAP | Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer | N/A | completed | 40 | Sichuan Provincial People's Hospital | May 2016 |
| NCT02515435 | The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer | P2 | unknown | 40 | Tongji University | Jan 2015 | |
| NCT02015169 | Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis | P2 | completed | 32 | Samsung Medical Center | Jul 2012 | |
| NCT02332512 | ANSWER | Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) | P3 | unknown | 417 | Jiangsu HengRui Medicine Co., Ltd. | Jan 2015 |
| NCT02238509 | Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | P2 | unknown | 154 | Consorzio Oncotech | Nov 2014 | |
| NCT02294786 | Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer | P2 | terminated | 62 | Novartis Pharmaceuticals | Dec 2014 | |
| NCT01589861 | PIKHER2 | Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer | P1/P2 | terminated | 24 | Institut Paoli-Calmettes | Dec 2011 |
| NCT02772029 | A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure | P1/P2 | unknown | 30 | The First Affiliated Hospital of Zhengzhou University | May 2016 | |
| NCT02525237 | Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer | P2 | unknown | 30 | Qingdao Municipal Hospital | Aug 2015 | |
| NCT00912275 | Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | P1/P2 | completed | 46 | National Taiwan University Hospital | Nov 2008 | |
| NCT02774200 | A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients. | P2 | unknown | 20 | Tianjin Medical University Cancer Institute and Hospital | May 2016 | |
| NCT02776527 | A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy | P4 | unknown | 40 | Tianjin Medical University Cancer Institute and Hospital | Apr 2016 | |
| NCT01934894 | Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | P2 | terminated | 11 | SCRI Development Innovations, LLC | May 2014 | |
| NCT01283789 | Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer | P2 | unknown | 23 | University of Kansas Medical Center | Feb 2011 | |
| NCT02409199 | A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer | P2/P3 | unknown | 66 | Shanghai Zhongshan Hospital | Jun 2015 | |
| NCT00486668 | A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer | P3 | unknown | 529 | NSABP Foundation Inc | Jul 2007 | |
| NCT00496366 | Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer | P2 | terminated | 11 | Rutgers, The State University of New Jersey | Jul 2007 | |
| NCT01332396 | Drug Use Investigation for TYKERB Tablet (All Case Investigation) | — | completed | 4,054 | Novartis | Jun 2009 | |
| NCT01044433 | Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck | P2 | completed | 44 | Abramson Cancer Center at Penn Medicine | Oct 2009 | |
| NCT02836171 | Effect of Itraconazole on the Pharmacokinetics of Apatinib | P1 | completed | 20 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2016 | |
| NCT02836821 | Effect of Rifampicin on the Pharmacokinetics of Apatinib | P1 | completed | 20 | Jiangsu HengRui Medicine Co., Ltd. | May 2016 | |
| NCT03491371 | Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use | N/A | completed | 56 | Peking University People's Hospital | Jun 2015 | |
| NCT02394496 | OVER | Overcoming Endocrine Resistance in Metastatic Breast Cancer | P3 | unknown | 396 | Consorzio Oncotech | Nov 2007 |
| NCT02691871 | Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR | P1 | unknown | 20 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Feb 2016 | |
| NCT01771458 | SHIVA | A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer | P2 | completed | 742 | Institut Curie | Oct 2012 |
| NCT01499160 | Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer | P2 | terminated | 7 | University of Maryland, Baltimore | May 2012 | |
| NCT01875666 | Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | Early P1 | completed | 26 | UNC Lineberger Comprehensive Cancer Center | Aug 2013 | |
| NCT01891357 | Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer | P2 | terminated | 64 | West German Study Group | Sep 2013 | |
| NCT02537171 | Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer | P3 | unknown | 40 | The Affiliated Hospital of the Chinese Academy of Military Medical Sciences | Jul 2015 | |
| NCT02338245 | Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab | P2 | completed | 200 | ASLAN Pharmaceuticals | Dec 2014 | |
| NCT02342587 | Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer | P2 | completed | 7 | Samsung Medical Center | Dec 2014 | |
| NCT00790816 | Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents | P1 | completed | 500 | Novartis Pharmaceuticals | Oct 2008 | |
| NCT01688609 | Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer | P2 | completed | 18 | National Cancer Institute (NCI) | Jul 2012 | |
| NCT00721630 | Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer | P2 | completed | 24 | Memorial Sloan Kettering Cancer Center | Jul 2008 | |
| NCT02768415 | Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer | P2 | unknown | 40 | Chinese Academy of Medical Sciences | Jun 2016 | |
| NCT00490061 | Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy | P2 | terminated | 17 | Quynh-Thu Le | Jul 2007 | |
| NCT02581124 | Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease | P1 | completed | 10 | Akros Pharma Inc. | Oct 2015 | |
| NCT01557764 | Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer | P2 | withdrawn | 0 | Washington University School of Medicine | Sep 2012 | |
| NCT01013740 | VITAL | Lapatinib in Combination With Vinorelbine | P2 | completed | 112 | Novartis Pharmaceuticals | Nov 2009 |
| NCT01434303 | Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | P1 | completed | 37 | National Cancer Institute (NCI) | Jan 2012 | |
| NCT02131506 | CAELYX | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer | P1 | terminated | 11 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Dec 2009 |
| NCT01497626 | Lapatinib and Bortezomib in Patients With Advanced Malignancies | P1 | terminated | 15 | Georgetown University | Sep 2011 | |
| NCT01309607 | Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer | P2 | unknown | 34 | National University Hospital, Singapore | Apr 2011 | |
| NCT00567554 | GeparQuinto | Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer | P3 | completed | 2,600 | GBG Forschungs GmbH | Oct 2007 |
| NCT00807859 | Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer | P1 | completed | 65 | Amgen | Mar 2009 | |
| NCT00516672 | Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors | P1 | completed | 30 | GlaxoSmithKline | Sep 2007 | |
| NCT01087983 | Lapatinib With Sirolimus or Metformin | P1 | completed | 111 | M.D. Anderson Cancer Center | Mar 2010 | |
| NCT00829166 | EMILIA | A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer | P3 | completed | 991 | Hoffmann-La Roche | Feb 2009 |
| NCT02683655 | Study of Apatinib in Metastatic Esophageal Cancer | P2 | unknown | 40 | Huai'an First People's Hospital | Aug 2015 | |
| NCT00524303 | Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. | P2 | completed | 100 | GlaxoSmithKline | Aug 2007 | |
| NCT01782651 | HER2 | Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients | — | completed | 1 | GlaxoSmithKline | Aug 2014 |
| NCT01868503 | Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer | P2 | terminated | 7 | Stanford University | Jul 2013 | |
| NCT01427322 | Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease | Early P1 | terminated | 6 | Virginia Commonwealth University | Sep 2011 | |
| NCT00883688 | Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | P2 | completed | 24 | M.D. Anderson Cancer Center | Jul 2009 | |
| NCT01985893 | THOR | Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer | P2 | withdrawn | 0 | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V. | Sep 2013 |
| NCT01534455 | E-VITA | Efficacy and Tolerability of Eribulin Plus Lapatinib in Patients With Metastatic Breast Cancer (E-VITA) | P2 | terminated | 43 | GBG Forschungs GmbH | Feb 2012 |
| NCT01328054 | A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval | P4 | completed | 58 | GlaxoSmithKline | Dec 2011 | |
| NCT01454804 | Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | P1 | completed | 43 | M.D. Anderson Cancer Center | Oct 2011 | |
| NCT00338247 | EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | — | approved for marketing | 0 | Novartis | Jul 2006 | |
| NCT00347919 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer | P2 | completed | 189 | GlaxoSmithKline | Jul 2006 | |
| NCT01769508 | Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer | P2 | terminated | 12 | SCRI Development Innovations, LLC | Feb 2013 | |
| NCT01138384 | Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer | P1/P2 | completed | 19 | NCIC Clinical Trials Group | Oct 2010 | |
| NCT00526669 | Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib | P2 | completed | 68 | GlaxoSmithKline | Mar 2008 | |
| NCT01395537 | GEJ | Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) | P1/P2 | terminated | 13 | Case Comprehensive Cancer Center | Aug 2011 |
| NCT01218529 | Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | P2 | completed | 82 | Hellenic Cooperative Oncology Group | Oct 2010 | |
| NCT00662636 | Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery | P1 | completed | 27 | Mayo Clinic | Aug 2008 | |
| NCT01531777 | Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer | P2 | completed | 40 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2011 | |
| NCT01495884 | The Myocet/Lapatinib Study. ICORG 10-03, V5 | P1/P2 | terminated | 11 | Cancer Trials Ireland | Mar 2011 | |
| NCT01658358 | ErbB2 Positive Metastatic Breast Cancer | P1/P2 | terminated | 15 | China Medical University Hospital | Jul 2012 | |
| NCT01123473 | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer | P2 | terminated | 29 | European Organisation for Research and Treatment of Cancer - EORTC | Dec 2010 | |
| NCT01176669 | Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients | P2 | completed | 60 | Fudan University | Jun 2010 | |
| NCT00118157 | Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen | P2 | completed | 19 | National Cancer Institute (NCI) | May 2005 | |
| NCT00863122 | Concentration and Activity of Lapatinib in Vestibular Schwannomas | Early P1 | completed | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Jun 2009 | |
| NCT00555152 | Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ | N/A | completed | 22 | National Cancer Institute (NCI) | Aug 2009 | |
| NCT01238029 | CELAVIE | Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | P1 | terminated | 12 | Sponsor GmbH | Oct 2010 |
| NCT00390455 | Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive | P3 | completed | 295 | National Cancer Institute (NCI) | Sep 2006 | |
| NCT01304784 | A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer | P1 | completed | 100 | Merrimack Pharmaceuticals | Jan 2011 | |
| NCT01161368 | A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients | P2 | terminated | 9 | Central European Cooperative Oncology Group | Sep 2010 | |
| NCT01275859 | Neo-All-In | Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer | P2 | completed | 25 | Asan Medical Center | Sep 2010 |
| NCT01454479 | A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma | P1 | unknown | 24 | Hung-Hsueh Chou | Mar 2011 | |
| NCT01287962 | Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | P3 | unknown | 480 | Sun Yat-sen University | Apr 2011 | |
| NCT01272141 | A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer | P2 | terminated | 5 | Emory University | Dec 2010 | |
| NCT01138046 | Phase I/II Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC | P2 | completed | 12 | GlaxoSmithKline | Apr 2010 | |
| NCT00548184 | Lapatinib and Trastuzumab With or Without Endocrine Therapy | P2 | completed | 65 | Baylor Breast Care Center | May 2008 | |
| NCT00387127 | Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer | P2 | completed | 67 | GlaxoSmithKline | Nov 2006 | |
| NCT01477060 | Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer | P2 | terminated | 32 | Fondazione Michelangelo | Nov 2011 | |
| NCT01281163 | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer | P1 | terminated | 4 | National Cancer Institute (NCI) | Jan 2011 | |
| NCT00841828 | Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients | P2 | completed | 102 | Spanish Breast Cancer Research Group | Feb 2009 | |
| NCT01172223 | LAPADO | Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer | P1/P2 | completed | 81 | Prof Dirk Elling | Sep 2007 |
| NCT00544804 | Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2 | P1 | completed | 41 | University of California, San Francisco | Aug 2007 | |
| NCT00356811 | Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer | P2 | completed | 57 | GlaxoSmithKline | May 2006 | |
| NCT00313599 | Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors | P1 | completed | 28 | University of California, San Francisco | Feb 2006 | |
| NCT01666431 | Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment | P2 | terminated | 10 | University of Zurich | Jun 2012 | |
| NCT01262469 | GERICO09 | Evaluating Lapatinib + Capecitabine in Patients Aged 70 and Over With HER2 Metastatic Breast Cancer. | P2 | completed | 4 | UNICANCER | Dec 2009 |
| NCT00424255 | Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery | P3 | completed | 688 | GlaxoSmithKline | Dec 2006 | |
| NCT01264081 | Lapatinib in Stage IV Melanoma With ERBB4 Mutations | P2 | terminated | 34 | National Cancer Institute (NCI) | May 2011 | |
| NCT01145404 | GastroLap | Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | P2 | terminated | 76 | National Center for Tumor Diseases, Heidelberg | Jun 2010 |
| NCT00756470 | Phase II Neoadjuvant in Inflammatory Breast Cancer | P2 | terminated | 15 | M.D. Anderson Cancer Center | Oct 2008 | |
| NCT01184482 | TYKERB-ITUX 1 | Lapatinib and Cetuximab in Patients With Solid Tumors | P1 | completed | 22 | Georgetown University | Jun 2010 |
| NCT00352443 | S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma | P1 | completed | 66 | SWOG Cancer Research Network | Sep 2006 | |
| NCT01077648 | Brain Metastasis in Breast Cancer Patients | — | completed | 1 | GlaxoSmithKline | Feb 2010 | |
| NCT00984425 | The Treatment of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors | P1 | completed | 30 | Istituto Clinico Humanitas | Sep 2009 | |
| NCT01192971 | HCC | A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma | P2 | completed | 121 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2010 |
| NCT00450892 | Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | P1/P2 | completed | 129 | European Organisation for Research and Treatment of Cancer - EORTC | Feb 2007 | |
| NCT00374322 | TEACH | Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer | P3 | completed | 3,166 | GlaxoSmithKline | Aug 2006 |
| NCT00881621 | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer | P2 | terminated | 17 | Georgetown University | Aug 2009 | |
| NCT00103194 | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer | P2 | completed | 49 | National Cancer Institute (NCI) | Sep 2005 | |
| NCT01512745 | Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer | P3 | completed | 267 | Jiangsu HengRui Medicine Co., Ltd. | Jan 2011 | |
| NCT00246753 | NRR | Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | P2 | completed | 29 | UNC Lineberger Comprehensive Cancer Center | Oct 2005 |
| NCT00795678 | Chemotherapeutic Agents in Brain/Breast | — | completed | 10 | Case Comprehensive Cancer Center | Sep 2008 | |
| NCT00953576 | KHLAD | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer | P1/P2 | terminated | 11 | Dana-Farber Cancer Institute | Sep 2009 |
| NCT01290354 | Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer | P1 | completed | 10 | GlaxoSmithKline | Sep 2011 | |
| NCT01199367 | Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer | P1 | terminated | 11 | Kyowa Kirin Co., Ltd. | Dec 2010 | |
| NCT00973739 | NF2 | Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | P2 | completed | 21 | NYU Langone Health | Sep 2009 |
| NCT00436644 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | P2 | completed | 18 | Mayo Clinic | Mar 2007 | |
| NCT00107003 | GW572016 to Treat Recurrent Malignant Brain Tumors | P2 | completed | 9 | National Cancer Institute (NCI) | Mar 2005 | |
| NCT01653561 | A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer | P2 | completed | 20 | Fudan University | Nov 2011 | |
| NCT01118975 | GCC 0845 | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | P1/P2 | terminated | 12 | University of Maryland, Baltimore | Mar 2010 |
| NCT00486954 | Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | P3 | completed | 273 | GlaxoSmithKline | Jul 2007 | |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | P1 | terminated | 60 | National Cancer Institute (NCI) | Sep 2012 | |
| NCT00996762 | A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib | P1 | completed | 158 | GlaxoSmithKline | Nov 2009 | |
| NCT00623064 | Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer | P1 | completed | 18 | European Organisation for Research and Treatment of Cancer - EORTC | Nov 2007 | |
| NCT00379509 | Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer | P1 | completed | 20 | UNC Lineberger Comprehensive Cancer Center | Apr 2006 | |
| NCT01471847 | A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab | P1 | completed | 5 | Novartis Pharmaceuticals | Feb 2012 | |
| NCT00470847 | Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer | P1 | completed | 35 | Nancy Lin, MD | Apr 2007 | |
| NCT00429299 | CHERLOB | Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer | P2 | completed | 121 | GlaxoSmithKline | Aug 2006 |
| NCT00903656 | Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy | P2 | terminated | 24 | Arbeitsgemeinschaft medikamentoese Tumortherapie | May 2009 | |
| NCT00709618 | Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects | P2 | terminated | 44 | GlaxoSmithKline | Jun 2008 | |
| NCT00952692 | Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer | P1/P2 | completed | 12 | Michael Morse, MD | Jul 2009 | |
| NCT00513058 | Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer | P1 | completed | 33 | UNICANCER | Jun 2007 | |
| NCT01005641 | ELBA | ELBA: Exemestane and Lapatinib in Advanced Breast Cancer | P2 | withdrawn | 0 | National Cancer Institute, Naples | Dec 2009 |
| NCT01128543 | Lapatinib in Combination With Vinorelbine | P2 | completed | 29 | GlaxoSmithKline | Apr 2009 | |
| NCT00753207 | Lapatinib and Epirubicin in Treating Patients With Metastatic Breast Cancer. ICORG 06-30 | P1 | completed | 10 | Cancer Trials Ireland | Oct 2007 | |
| NCT00075270 | Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | P3 | completed | 580 | GlaxoSmithKline | Jan 2004 | |
| NCT00206427 | GW | Neoadjuvant GW572016 to Treat Breast Cancer | P2 | completed | 49 | Baylor Breast Care Center | Aug 2004 |
| NCT00842998 | HERLAP | Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer | P2 | unknown | 120 | Azienda Ospedaliera Ordine Mauriziano di Torino | Feb 2009 |
| NCT00558103 | Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | P2 | completed | 163 | GlaxoSmithKline | Dec 2007 | |
| NCT00389922 | Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors | P1 | completed | 22 | University of California, Davis | Dec 2005 | |
| NCT00963547 | MK-2206-015 | A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | P1 | terminated | 33 | Merck Sharp & Dohme LLC | Sep 2009 |
| NCT00694252 | Lapatinib and Circulating Tumor Cells in Breast Cancer | P2 | completed | 20 | University Hospital of Crete | Jul 2008 | |
| NCT01245660 | LAPAINBLAD | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy | Early P1 | terminated | 3 | University Hospital, Bordeaux | Jan 2011 |
| NCT01133912 | PGT | Preoperative Chemotherapy With Paclitaxel, Gemcitabine, and Lapatinib (Tykerb®) (PGT) | P1 | completed | 13 | Jungsil Ro | Mar 2009 |
| NCT00225758 | Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | P2 | terminated | 27 | Gary Schwartz | Jan 2006 | |
| NCT01270386 | A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer | P2 | completed | 136 | Jiangsu HengRui Medicine Co., Ltd. | Mar 2010 | |
| NCT01050322 | GLICO-0801 | Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. | P2 | completed | 142 | Latin American Cooperative Oncology Group | Nov 2009 |
| NCT00804310 | UCDCC#207 | Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors | P1 | terminated | 5 | University of California, Davis | Aug 2009 |
| NCT00299286 | MAPLE | Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer | P2 | completed | 121 | Institute of Cancer Research, United Kingdom | Jun 2007 |
| NCT00316875 | Lapatinib and Doxorubicin Hydrochloride Liposome in Treating Patients With Metastatic Breast Cancer | P1 | completed | 23 | Northwestern University | May 2006 | |
| NCT00820924 | Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells | P2 | terminated | 23 | GlaxoSmithKline | Jun 2008 | |
| NCT00632489 | LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients | P1 | completed | 20 | SCRI Development Innovations, LLC | May 2008 | |
| NCT00482391 | Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer | P2 | completed | 95 | Memorial Sloan Kettering Cancer Center | Mar 2007 | |
| NCT00430781 | Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer | P2 | completed | 228 | GlaxoSmithKline | Nov 2006 | |
| NCT00614978 | LAPTEM | Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer | P1 | completed | 18 | Jules Bordet Institute | Jan 2008 |
| NCT00422903 | Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer | P2 | completed | 92 | GlaxoSmithKline | Apr 2007 | |
| NCT00754702 | Vinorelbine Metronomic Plus Lapatinib for Overexpressing HER-2 Metastatic Breast Cancer | P2 | terminated | 16 | University Hospital of Crete | Oct 2008 | |
| NCT00682279 | A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors | P1 | withdrawn | 0 | GlaxoSmithKline | Sep 2008 | |
| NCT00404066 | Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | P2 | completed | 21 | George Albert Fisher | Oct 2006 | |
| NCT00113373 | Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | P2 | completed | 28 | National Cancer Institute (NCI) | May 2005 | |
| NCT00096447 | Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | P2 | completed | 31 | National Cancer Institute (NCI) | Nov 2004 | |
| NCT00821054 | A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients | P1 | completed | 24 | GlaxoSmithKline | Mar 2009 | |
| NCT01205217 | ELATE | Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer | P2 | withdrawn | 0 | GlaxoSmithKline | Dec 2010 |
| NCT01068704 | Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer | P2 | completed | 4 | Bristol-Myers Squibb | Jun 2010 | |
| NCT00970138 | Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer | P2/P3 | completed | 141 | Fudan University | Jun 2009 | |
| NCT00499681 | PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE | P2 | terminated | 6 | Vanderbilt-Ingram Cancer Center | Jul 2007 | |
| NCT00477464 | Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer | P2 | completed | 51 | GlaxoSmithKline | Jun 2007 | |
| NCT01245205 | Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer | P1 | completed | 28 | National Cancer Institute (NCI) | Nov 2010 | |
| NCT00320385 | Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer | P3 | completed | 296 | GlaxoSmithKline | Nov 2005 | |
| NCT00857714 | DCIS | Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast | N/A | terminated | 1 | Indiana University | Apr 2009 |
| NCT00331630 | Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | Early P1 | completed | 30 | Northwestern University | May 2006 | |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | P1/P2 | completed | 52 | National Cancer Institute (NCI) | Oct 2004 | |
| NCT00634088 | HER2 | Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer | P1 | terminated | 13 | R-Pharm | Jun 2008 |
| NCT00105950 | Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer | P2 | completed | 126 | GlaxoSmithKline | Mar 2005 | |
| NCT00424164 | LAPATAM | Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer | P1 | completed | 20 | European Organisation for Research and Treatment of Cancer - EORTC | Nov 2006 |
| NCT00479856 | Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer | P2 | terminated | 9 | GlaxoSmithKline | Nov 2007 | |
| NCT00437073 | Brain Metastases In ErbB2-Positive Breast Cancer | P2 | terminated | 22 | GlaxoSmithKline | May 2007 | |
| NCT00078572 | XELODA | Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer | P3 | completed | 408 | GlaxoSmithKline | Mar 2004 |
| NCT00350727 | VEG102857 | Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma | P2 | completed | 75 | GlaxoSmithKline | Dec 2006 |
| NCT00343759 | Presurgical Therapy With Lapatinib to Explore Molecular Determinants of Response to EGFR/erbB2 Targeted Therapy | P2 | withdrawn | 0 | University of Pennsylvania | Jun 2006 | |
| NCT00316407 | Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients | P1/P2 | completed | 30 | Swedish Medical Center | Aug 2005 | |
| NCT00849329 | A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer | P1 | completed | 12 | GlaxoSmithKline | Mar 2009 | |
| NCT00657137 | APRiCOT-B | APRiCOT-B: Study to Evaluate Apricoxib in Combination With Lapatinib and Capecitabine in the Treatment of HER2/Neu+ Breast Cancer (TP2001-202) | P2 | terminated | 12 | Tragara Pharmaceuticals, Inc. | Apr 2008 |
| NCT00447226 | Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists | P2 | terminated | 32 | GlaxoSmithKline | May 2007 | |
| NCT00574171 | Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma | P2 | completed | 29 | University of Wisconsin, Madison | Sep 2007 | |
| NCT00388076 | VOTRIENT | Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | P1 | completed | 86 | GlaxoSmithKline | Apr 2006 |
| NCT00650910 | Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer | P1 | completed | 17 | GlaxoSmithKline | Apr 2008 | |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | P2 | completed | 40 | National Cancer Institute (NCI) | Sep 2004 | |
| NCT00107536 | Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | P2 | completed | 26 | National Cancer Institute (NCI) | Oct 2005 | |
| NCT00528281 | TYKERB | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | P1 | completed | 18 | GlaxoSmithKline | Sep 2007 |
| NCT00967031 | Lapatinib Ditosylate and Capecitabine in Treating Patients With Stage IV Breast Cancer and Brain Metastases | P2 | completed | 45 | UNICANCER | Apr 2009 | |
| NCT00769470 | Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery | P2 | completed | 18 | Translational Oncology Research International | Apr 2009 | |
| NCT00320411 | GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer | P2 | completed | 62 | GlaxoSmithKline | Nov 2005 | |
| NCT00949455 | LaMB | A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium | P2/P3 | unknown | 204 | Queen Mary University of London | Mar 2009 |
| NCT00498953 | Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx | P1/P2 | completed | 7 | European Organisation for Research and Treatment of Cancer - EORTC | May 2007 | |
| NCT00962312 | Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer | P2 | completed | 9 | Cancer Trials Ireland | Jan 2009 | |
| NCT00826267 | 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab | P2 | completed | 29 | Boehringer Ingelheim | Jan 2009 | |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | P2 | completed | 57 | National Cancer Institute (NCI) | Nov 2004 | |
| NCT01044485 | LapDoc | Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | P1/P2 | completed | 17 | Centre Georges Francois Leclerc | Nov 2008 |
| NCT00536809 | Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer | P1 | completed | 12 | GlaxoSmithKline | Sep 2007 | |
| NCT00447122 | BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer | P1 | terminated | 25 | Brown University | Mar 2007 | |
| NCT00898573 | Lapatinib Resistance in Patients With Breast Cancer | — | withdrawn | 0 | Case Comprehensive Cancer Center | Jul 2008 | |
| NCT00073008 | A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer | P2 | terminated | 131 | GlaxoSmithKline | Nov 2003 | |
| NCT00633490 | Study of Apatinib as an Inhibitor of Tumor Angiogenesis | P1 | unknown | 18 | Fudan University | Jul 2007 | |
| NCT00688194 | Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | P3 | unknown | 396 | Gruppo Italiano Mammella (GIM) | May 2008 | |
| NCT00513253 | A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib | P1 | withdrawn | 0 | GlaxoSmithKline | Apr 2008 | |
| NCT00888810 | TOPO-LAPA | Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer | P2 | terminated | 39 | Centre Francois Baclesse | Mar 2008 |
| NCT00089999 | Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer | P2 | completed | 138 | GlaxoSmithKline | Jun 2004 | |
| NCT00359190 | Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer | P1 | completed | 28 | GlaxoSmithKline | Jun 2004 | |
| NCT00371566 | A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer | P2 | completed | 107 | GlaxoSmithKline | Mar 2006 | |
| NCT00099060 | Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme | P1/P2 | completed | 24 | National Cancer Institute (NCI) | Dec 2004 | |
| NCT00239200 | GW572016 | Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus | P2 | terminated | 29 | University of Michigan Rogel Cancer Center | Oct 2005 |
| NCT00158782 | Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients | P1 | completed | 75 | GlaxoSmithKline | Sep 2004 | |
| NCT00495872 | Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor | P1 | completed | 204 | M.D. Anderson Cancer Center | Jun 2007 | |
| NCT00259987 | GW572016 | Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus | P2 | completed | 24 | GlaxoSmithKline | Nov 2005 |
| NCT00317434 | Maximum Tolerated Dose of Lapatinib When Given With Carboplatin for Recurrent Ovarian Cancer | P1 | terminated | 12 | University of Alabama at Birmingham | Nov 2005 | |
| NCT00258050 | To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients | P1 | completed | 24 | GlaxoSmithKline | Nov 2005 | |
| NCT00111787 | Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | P2 | completed | 49 | GlaxoSmithKline | Apr 2005 | |
| NCT00114283 | Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | P2 | completed | 30 | National Cancer Institute (NCI) | Mar 2005 | |
| NCT00148902 | TAXOTERE | Effects Of GW572016 In Combination With Docetaxel (TAXOTERE) | P1 | completed | 52 | GlaxoSmithKline | Apr 2003 |
| NCT00085020 | GW572016 and Trastuzumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu | P1 | completed | 13 | Jonsson Comprehensive Cancer Center | Mar 2004 | |
| NCT00103324 | S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer | P2 | completed | 40 | National Cancer Institute (NCI) | Dec 2004 | |
| NCT00095667 | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer | P2 | completed | 41 | National Cancer Institute (NCI) | Nov 2004 | |
| NCT00098631 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | P2 | completed | 88 | National Cancer Institute (NCI) | Oct 2004 | |
| NCT00098605 | Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases | P2 | completed | 37 | National Cancer Institute (NCI) | Oct 2004 | |
| NCT00044343 | GW572016 | GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin | P2 | completed | 80 | GlaxoSmithKline | Sep 2002 |
Apatinib clinical trials: frequently asked questions
- How many Apatinib clinical trials are there?
- 787 Apatinib clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 75 are actively recruiting participants. 255 are marked completed.
- Are Apatinib clinical trials recruiting in 2026?
- Yes — 75 Apatinib trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Apatinib being studied for?
- Apatinib is being studied for Breast Cancer, Neoplasms, Breast, Gastric Cancer, Hepatocellular Carcinoma, Metastatic Breast Cancer and 621 more. The trials are grouped by indication on this page.
- What phase is Apatinib in?
- Apatinib clinical trials span 10 Phase 4, 84 Phase 3, 476 Phase 2, 94 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Apatinib clinical trials?
- The lead sponsor across the most Apatinib trials is GlaxoSmithKline, with 297 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Apatinibas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: